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DEVELOPMENT OF BAR-PEPTIDE NANOPARTICLES AND ELECTROSPUN 
FIBERS FOR THE PREVENTION AND TREATMENT OF ORAL BIOFILMS 
Mohamed Yehia Mahmoud 
April 18, 2019 
Background: Periodontal diseases are globally prevalent inflammatory disorders 
that affect ~47% of U.S adults. Porphyromonas gingivalis (Pg) has been identified 
as a “keystone” pathogen that disrupts host-microbe homeostasis and contributes 
to the initiation and progression of periodontitis. Pg associates with oral 
streptococci in supragingival plaque and this interaction represents a potential 
target for therapeutic intervention. Previously our group developed a peptide 
(designated BAR), that potently inhibits Pg/Streptococcus gordonii (Sg) adherence 
in vitro and Pg virulence in a murine model of periodontitis. While efficacious, BAR 
(SspB Adherence Region) provided transient inhibition and required higher 
concentrations of BAR to disrupt established biofilms.  
Hypothesis and Aims: To address these challenges, we hypothesized that BAR-
surface modified and BAR-encapsulated poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles (NPs) may more potently inhibit and disrupt biofilms in vitro and in 
vivo, relative to free BAR. 
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In addition, a new rapid-release platform, composed of polymeric electrospun 
fibers (EFs) that encapsulate BAR peptide, was developed. Given this, our 
objectives were to evaluate BAR-surface modified NPs in a murine model of 
periodontitis; to fabricate and assess the ability of BAR-encapsulated NPs to inhibit 
and disrupt in vitro oral biofilm formation, and to evaluate a new dosage form, 
electrospun fibers, to inhibit andformation, and to evaluate a new dosage form, 
electrospun fibers, to inhibit and disrupt in vitro oral biofilm formation. In addition, 
the safety of all platforms was determined via viability, apoptosis, adenosine 
triphosphate (ATP), lactate dehydrogenase (LDH) and oxidative DNA assays 
using telomerase immortalized gingival keratinocytes (TIGKs). 
Methods: BAR-encapsulated and BAR-surface modified PLGA NPs were 
synthesized using adapted double- and single-emulsion techniques, respectively. 
Electrospun fibers were formed using a uniaxial approach, with different 
hydrophobic polymers (PLGA, polycaprolactone, poly(L-lactic acid)); each blended 
with different polyethylene oxide ratios (PEO: 0, 10, 20, or 40% w/w) to achieve 
maximal release of BAR. Both BAR-encapsulated NPs and EFs were assessed 
for inhibition of two-species biofilm formation and for disruption of pre-existing 
biofilms, against an equimolar free BAR concentration.  In vivo efficacy of BAR-
surface modified NPs was assessed using a murine model of periodontitis by 
measuring alveolar bone resorption and gingival IL-17 expression as outcomes of 
Pg-induced inflammation.  
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Results: BAR-encapsulated NPs and EFs inhibited biofilm formation (IC50s = 0.7 
and 1.3 μM, respectively) in a dose-dependent manner, relative to free BAR (IC50 
= 1.3 µM). In addition, BAR-encapsulated NPs and EFs efficiently disrupted 
established dual-species biofilms (IC50s = 1.3 and 2 μM, respectively). Treatment 
of Pg/Sg infected mice with BAR-surface modified NPs reduced alveolar bone loss 
and IL-17 expression almost to the levels of sham-infected mice and to a greater 
extent than treatment with an equimolar amount of free BAR. The in vitro 
cytotoxicity studies, which utilized the maximum concentration of BAR-
encapsulated NPs, BAR-surface modified NPs, BAR EFs, and free BAR (1.3 and 
3.4 μM) demonstrated > 90% viability for all samples and showed no significant 
lysis or apoptosis relative to untreated cells. In addition, all tested formulations 
exhibited a lack of hemolytic activity. 
Conclusion: These data suggested that BAR NPs and EFs provide novel and 
potent platforms to inhibit and disrupt dual-species biofilms. All formulations 
exhibited minimal cellular toxicity or hemolytic activity, highlighting the potential of 
NPs and EFs as a biocompatible platform for translatable oral biofilm applications. 
Chapters included in this dissertation represent papers that have been submitted, 
which may result in duplicate descriptions across chapters; however, these have 
been provided for the sake of completeness. Chapter 2 has been published in the 
Journal of Nanobiotechnology and Chapter 3 has been published in the Journal of 
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CHAPTER 1  
BACKGROUND AND SIGNIFICANCE 
Periodontal diseases are multifactorial common chronic diseases that 
destroy the tooth-supporting tissues and subsequently lead to alveolar bone loss 
and finally tooth loss. Periodontal diseases are also associated with increased risk 
for multiple systemic diseases including cardiovascular disease, diabetes, 
rheumatoid arthritis, pulmonary disease, and obesity1,2. Periodontal diseases are 
globally prevalent diseases with the worldwide economic impact of direct treatment 
estimated at US $298 billion yearly, corresponding to an average of 4.6% of global 
health expenditures3-6. 
Gingivitis is a mild form of periodontal disease that is caused by bacterial 
colonization in the subgingival pocket leading to the formation of a biofilm (dental 
plaque). Gingivitis is usually diagnosed through the clinical signs of inflammation 
(erythema, edema, pain), bleeding and discomfort on gentle probing, and halitosis. 
Chronic gingivitis often results in mild bleeding from the gums during tooth 
brushing, which is generally only a minor inconvenience unless underlying blood 
dyscrasias or bleeding disorders exist7. Gingivitis is a reversible disease that can 
be resolved following treatment of gingival inflammation by proper oral health care 
to reduce gingival pocket depths to ≤ 3 mm.
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 An acute form of gingivitis (necrotizing ulcerative gingivitis) is characterized 
by gingival necrosis, bleeding, ulcerated papillae, severe gingival swelling and 
pain. Untreated ulcerative gingivitis may lead to rapid destruction of the 
periodontium resulting in necrotizing ulcerative periodontitis and can even spread 
as necrotizing stomatitis, into neighboring tissues in the cheeks, lips or the bones 
of the jaw8. Untreated gingivitis and poor oral health care can progress to 
periodontitis which exhibits  a chronic inflammatory response that ultimately results 
in the  destruction of connective tissue, resorption of alveolar bone and tooth loss7. 
Chronic periodontitis results in irreversible tissue damage that remains for life and 
requires diligent protective care to prevent disease recurrence9. Individuals with 
advanced periodontitis may also have recurrent periodontal abscesses and 
halitosis. The clinical diagnosis of chronic periodontal disease depends on visual 
and radiographic assessment of the periodontal tissues, and measurements of 
subgingival pocket depths (≥ 5 mm)7.  
Aggressive periodontitis results in more rapid attachment loss and bone 
destruction and can occur earlier in life, often in children as young as 8 yr old. 
Secondary characteristics of aggressive periodontitis are described by the 
presence of relatively low levels of gingival bacteria although commonly, 
Aggregatibacter actinomycetemcomitans and Pg are the most abundant 
organisms associated with the disease10. In addition to rapid and severe 
periodontal tissue destruction, aggressive periodontitis is characterized by a 
hyper-responsive phenotype characterized by an increased inflammatory 
response upon stimulation of innate immune cells11. 
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Periodontal diseases are also associated with a variety of systemic 
conditions.  For example, periodontal diseases are associated with preterm births, 
which might be attributed to infection of decidual tissues by periodontal pathogens 
through bacteraemia or to an inflammatory cascade that results from systemic 
circulation of inflammatory mediators produced in the periodontal tissues12. 
Previous studies demonstrated that intravenous injection of pregnant mice with 
periodontal bacteria leads to premature delivery and stillbirths13. However, it is 
important to note that currently there is no direct causal evidence that periodontal 
pathogens can cause preterm birth in humans and these organisms are not 
associated with chorioamnionitis, positive placental cultures, or markers of upper 
genital tract inflammation14.  
Periodontal diseases may also have a potential role in the initiation or 
progression of coronary artery disease and stroke15. These effects may be 
attributed to increasing levels of C-reactive protein, fibrinogen, and cytokines, 
which have been linked to atherosclerosis-induced disease. In addition, a previous 
study showed that treatment of periodontal disease reduced serum inflammatory 
markers and C-reactive protein16 and other studies demonstrated that periodontal 
pathogens promote platelet aggregation and induce foam cell formation17. Finally, 
several additional studies suggested that a systemic antibody response to several 
periodontal pathogens was associated with coronary heart disease, stroke, and 
increased intima media thickening18-20. 
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Periodontitis and rheumatoid arthritis are common chronic inflammatory 
diseases with very high morbidity worldwide. Previous studies showed that 
individuals with both periodontitis and rheumatoid arthritis may have more missing 
teeth and greater inflammation relative to periodontitis patients without rheumatoid 
arthritis21.  Pg produces a proteolytic enzyme, Pg peptidyl-arginine deiminase 
(PPAD), which has the ability to convert arginine residues in proteins to citrulline. 
Citrullination of proteins can alter protein assembly and function and consequently 
deregulate immune evasion. Moreover, chronic exposure to citrullinated proteins 
that may exist in periodontitis patients may predispose susceptible individuals to 
the development of autoantibodies and the initiation of rheumatoid arthritis22  
Periodontal diseases are also a possible complication of diabetes. 
Treatment of periodontal disease has been shown to enhance diabetic control23. 
Periodontal disease might also be an important predictor of deaths from ischaemic 
heart disease and diabetic nephropathy, but not from other causes24.   
Finally, periodontal diseases may be associated with various pulmonary 
infections25. Pathogens causing pneumonia have been shown to colonize the oral 
cavity of high-risk individuals26, and initial studies indicate that proper oral hygiene 
can reduce the rate of respiratory infections27. 
The gold standard for treatment of periodontal disease is instrumental 
debridement of dental plaque followed by antibiotic administration and surgery to 
reduce subgingival pocket depth if necessary28,29. Although mechanical 
debridement has proven effective for treating periodontal diseases30, this approach 
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has several limitations, For example, individual patients may not respond uniformly 
and favorably to treatment31, scaling instruments may be unable to fully penetrate 
deep subgingival pockets, mechanical debridement may be ineffective against 
certain pathogens, and the presence of other adverse conditions including tooth 
loss, dentin hypersensitivity, and gingival collapse may decrease the effectiveness 
of mechanical treatment strategies32,33. As a result, antibiotic administration, in 
combination with mechanical debridement has been recommended to suppress 
periodontal pathogenic bacterial colonization and improve clinical outcomes30,34.  
Despite the advantages that adjunct localized or systemic antibiotics can 
provide, these treatment strategies often exhibit non-specific activity and affect 
beneficial organisms present in the oral cavity. Antibiotics may also fail to 
effectively penetrate the oral biofilms. Additional potential risks include the 
development of resistant species, emergence of fungal opportunistic infections, 
and potential allergic reactions35-37.  
Many factors can influence the initiation and progression of periodontal 
disease including genetic predisposition, health status of the host, environmental 
factors, and risk factors such as diet and stress. In addition, the subgingival 
microbial community plays a vital role in periodontitis development. The role of 
bacteria in periodontitis can be illustrated by two main hypotheses. The non-
specific plaque hypothesis suggests that no specific bacteria plays a role in 
periodontitis development. This hypothesis postulates that the host innate immune 
response keeps oral organisms and putative virulence factors under control and 
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disease only develops if the host immune response becomes compromised and 
bacterial virulence factors can no longer be neutralized. Since plaque of any 
composition can potentially cause disease, the best preventative approach would 
be mechanical removal of plaque38.  
In contrast, the specific plaque hypothesis purports that specific microbial 
species are associated with  periodontitis progression39. Early studies suggested 
that many organisms might be associated with periodontitis, including protozoa, 
spirochetes, streptococci; actinomyces, Gram-negative anaerobic organisms, and 
facultative anaerobic Gram-negative organisms of the genera Capnocytophaga, 
Eikenella and Actinobacillus40. More recently, Socransky et al. identified the ‘red 
complex’ of organisms, composed of a group of three species including 
Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia, and 
showed that these organisms predominate  in the pathogenic dental plaque 
isolated from symptomatic subgingival sites of periodontitis patients41. However, a 
limitation of the specific plaque hypothesis is that it does not completely explain 
the absence of putative periodontal pathogens in some diseased individuals or the 
presence of these pathogenic organisms in healthy individuals42. In addition, a 
further limitation relates to the large number of uncultivable species43 in the oral 
microbiome which creates bias toward easily cultivable species44. This hypothesis 
proposed that the use of antibiotics against specific bacterial species could 




More recently, a modified hypothesis has been proposed suggesting that 
changes in environmental factors may lead to a shift in the resident microflora 
resulting in microbial dysbiosis and that specific bacteria may contribute to the 
disruption of normal host-microbe homeostasis. Indeed, Pg is a gram negative 
anaerobic bacterium and has been found to be present in 88% of sub-gingival 
plaque samples isolated from chronic periodontitis patients45. Pg has been 
identified as a “keystone pathogen” due to its ability to disrupt the host complement 
pathway, leading to a change in the microflora from a symbiotic microbiota to a 
dysbiotic community even though Pg may be present in low abundance46,47. This 
recent study demonstrated that Pg-infected mice showed reduced innate 
immunity, increased oral microbial biomass, and significant changes in the 
composition of the periodontal microbiota leading to the induction of inflammatory 
bone loss. Consistent with the keystone pathogen hypothesis, Pg only induced 
inflammatory bone loss in wild type mice and was avirulent in germ free animals 
that lacked the indigenous oral microbiota48.  
Although the keystone pathogen hypothesis was initially established from 
studies conducted in a mouse model, it was consistent with observations in other 
animal models and in humans42. For example, it was shown that infection by Pg 
increased bacterial biomass of the dental biofilm in rabbit49 and the use of a 
vaccine against Pg decreased total subgingival bacterial counts in non-human 
primates (Macaca fascicularis)50. Pg has also been shown to alter the host immune 
response in other ways as well.  A previous in vitro study showed that Pg inhibits 
the stimulation of gingival interleukin-8 like chemokines which may delay the 
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infiltration of neutrophils, consequently enabling its initial colonization and 
enhancing the growth of other organisms51. This study also revealed that the 
capability of Pg to persist in the periodontium relies on complement C5 convertase 
activity of its proteolytic enzymes and destructive crosstalk between the C5a 
receptor and toll-like receptor 248. 
  Pg initially adheres to primary colonizers of the oral cavity, i.e., commensal 
streptococci (e.g., Streptococcus gordonii) before becoming established in its ideal 
niche, the anaerobic environment of subgingival dental plaque52. In efforts to 
establish a more mechanistically-specific treatment or prophylactic modality, the 
recent identification of pathogenic mechanisms in polymicrobial communities and 
their relation to pathways of immune response have begun to elucidate targets 
relevant to inflammatory and disease states. As stated above, biofilm formation 
and bacterial colonization are initially prompted by association of Pg with oral 
streptococci in the supragingival niche, and this represents an ideal target for 
therapeutic intervention. 
Previous studies suggested that Pg adherence to Sg is mediated by a 
protein-protein interaction that occurs between the minor fimbrial antigen (Mfa) of 
Pg and specific members of the antigen I/II family of proteins expressed by 
commensal streptococci, e.g., the SspB protein of Sg (Figure 1.1)53.  In addition, 
the region comprising amino acid residues 1167 to 1250 of the SspB polypeptide 
sequence was shown to be essential for adherence to Pg54 and additional studies 
showed that within this region of SspB, amino acids 1167 to 1193 designated as 
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BAR (SspB Adherence Region) were required for adherence of Pg53.  These 
studies also demonstrated that a synthetic peptide encompassing the BAR motif 
potently inhibited biofilm formation by Pg and Sg in vitro and reduced virulence of 
Pg in a murine model of infection [refs]. While efficacious, the effectiveness of BAR 
as a potential therapeutic may be limited by the duration of exposure within the 
oral cavity and the increased complexity of the oral microbiome in humans. Indeed, 
higher concentrations of BAR were required to disrupt established in vitro 
biofilms15,17. To address these delivery challenges, our goal was to develop a drug 
delivery system for BAR peptide that specifically targets Pg while providing higher 




Figure 1.1 Mechanism of Pg–Sg co-aggregation. Adapted from Trends in 
Molecular Medicine, 21(3), 172-183. 
Despite the attributes that delivery vehicles offer to biologic and drug 
delivery, there is currently a scarcity of drug delivery vehicles that enable specific 
and prolonged delivery of active agents to the oral cavity. One option to provide 
higher localized concentrations and prolonged delivery is to use polymeric 
nanoparticles (NPs)55. The advantages of using NP delivery vehicles include the 
ability to: 1) highly encapsulate and deliver one or multiple active agents 
simultaneously; 2) protect the stability of active agents, especially molecules with 
11 
 
shorter half-lives (e.g. peptides); 3) provide tunable release and prolonged delivery 
of active agent; 4) facilitate penetration to target specific niches in cells and tissue; 
and 5) enable subsequent localization of active agent in target sites 56. 
A variety of nanoparticle platforms exist, fabricated from metals57,58, 
semiconducting materials59, ceramics60-63, lipids64,65, and polymers66,67. For dental 
applications specifically, metallic and metal oxide particles, made from silver68-71, 
gold72,73, copper74-76, zinc77,78 and titanium78 have demonstrated antimicrobial 
properties in the oral microenvironment and have been utilized in the treatment of 
periodontal diseases. However, this inhibition is non-specific in nature, resulting 
from primarily electrostatic interactions with bacterial cells, subsequently 
decreasing bacterial replication or reduction of ATP production79-81. Moreover, 
there have been several concerns regarding the toxicity associated with metallic 
NPs and their accumulation in various tissues and organs82-84. 
Polymeric NPs have been widely utilized to deliver antibiotics to the oral 
cavity85,86, and to avoid challenges of cytotoxicity and harmful accumulation of toxic 
metabolites observed after administration of metallic NPs. Moreover, polymeric 
NPs may offer biodegradability without toxic residues, and may be tailored to 
control the rate and duration of drug delivery. These attributes may be helpful to 
deliver high concentrations of active agents to target sites and to maintain 
functional activity of these agents for prolonged durations. Last, polymer NPs may 
be designed with mucoadhesive characteristics to adhere to oral tissue, thereby 
increasing the local concentration of active agents55,56,61,66. 
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PLGA NPs have been FDA-approved and widely studied for drugs, protein, 
RNA and DNA delivery applications. PLGA NPs degrade into relatively inert 
metabolic by-products, poly(lactic acid) (PLA) and poly(glycolic acid) (PGA), 
enabling safe, biocompatible, and non-toxic delivery of associated cargo86-91. As 
one example of antibiotic delivery, a previous study showed that minocycline-
loaded PLGA NPs had potent antibacterial activity against Aggregatibacter 
actinomycetemcomitans infection with a minimum inhibitory concentration two 
times lower than free minocycline92. 
Despite the utility of NPs to deliver antibiotics to treat periodontitis, high 
doses of antibiotics are needed to establish inhibitory concentrations in the 
subgingival pockets, which may result in antibiotic resistance and adverse side 
effects37. Moreover, non-specific inhibition decreases the viability of commensal 
flora in the oral cavity, potentially causing fungal, viral and other bacterial 
infections. Due to these challenges, there is a need to develop targeted, sustained-
release delivery vehicles that can specifically target Pg, a predominant pathogen 
in severe periodontitis, and provide higher localized concentrations of active 
agents for longer duration in the oral cavity93,94.  
Our preliminary studies have suggested that PLGA NPs that are surface-
modified with BAR peptide increase the effectiveness of peptide-mediated 
inhibition of Pg/Sg adherence. Recently we demonstrated that this increased 
effectiveness is attributed to specific multivalent interactions between NPs and Pg. 
BAR-modified PLGA NPs enhanced BAR potency by promoting a multivalent 
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binding interface, thus increasing the avidity of BAR with Pg95,96. Building upon this 
previous work, we next wanted to evaluate BAR-surface modified NPs in an in vivo 
murine model of infection and to increase the duration of exposure by developing 
sustained-release nanoparticles that control the release of BAR peptide to promote 
longer exposure time (12-24 hr) in the oral cavity. Our premise was that the 
incorporation of BAR peptide in PLGA NPs may provide sustained-release of BAR 
peptide, while BAR-surface modification offered a platform that provides higher 
localized concentration of BAR in the oral cavity.  
Recently, polymeric electrospun fibers have been widely used in oral drug 
delivery97,98. EFs may complement the delivery of, or offer advantages to NPs, 
including higher drug loading; more tunable modulation of drug release, dependent 
on the polymer properties; and less susceptibility to removal  by salivary flow, 
resulting in longer retention in the oral cavity99-101.  A variety of natural, synthetic, 
semi-synthetic and biological polymers are used to provide biocompatibility and 
biodegradablility.  FDA-approved polymers including PLGA102, poly(L-lactic acid) 
(PLLA)103, polycaprolactone (PCL)97, and polyethylene oxide (PEO)104 have been 
successfully used for drug delivery. In addition, fibers have the capacity to serve 
as a more durable delivery vehicle, providing enhanced retention in the oral cavity 
and ensuring active agent release within the oral cavity versus in the digestive 
tract. This durability may also offer a more convenient administration method, 
similar to films, but with the capability of providing prolonged release in desired 
applications. Given these attributes, we envisioned that designing EFs targeted to 
the oral cavity may provide a new dosage form in which to administer BAR, and 
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may provide a mechanism to improve therapeutic outcomes by increasing the 
localized concentration of BAR. We anticipated that completion of these aims 
would increase BAR effectiveness and longevity of exposure without influencing 
other commensal or beneficial bacteria that reside in the oral cavity. Moreover, the 
successful achievement of these objectives will provide new platforms for the 
delivery of BAR peptide in the oral cavity, with the potential to translate prevention 
and treatment to clinical practice. We envision that these research outcomes will 
have a significant impact on controlling a costly and widespread disease and may 









BAR-ENCAPSULATED NANOPARTICLES FOR THE INHIBITION AND 
DISRUPTION OF PORPHYROMONAS GINGIVALIS-STREPTOCOCCUS 
GORDONII BIOFILMS 
Introduction 
Periodontal disease is a group of chronic inflammatory diseases commonly 
caused by Porphyromonas gingivalis, Tannerella forsythia, and Treponema 
denticola. Together these pathogens are known as the “red complex”36. The 
progression of periodontal disease can cause tissue destruction and tooth loss, 
and if left untreated can contribute to systemic conditions of increased cancer risk, 
cardiovascular disease, diabetes, rheumatoid arthritis, pulmonary disease, and 
obesity1,2.   
Current periodontal treatments aim to reduce bacterial plaque formation in 
the oral cavity using primarily physical and chemical (antibiotic) methods105,106. 
However, current antibiotic treatment strategies exhibit non-specific activity, 
affecting beneficial organisms also present in the oral microbiome. Additional 
potential risks include the development of anti-bacterial resistant species, 




Last, most current antibiotics have difficulty penetrating periodontal biofilms, 
and must be frequently administered, due to their transient activity in the oral 
cavity35,37,107. 
Pg has been found to be associated with chronic periodontitis in 88% of 
sub-gingival plaque samples23. Moreover, Pg and Sg association enhances the 
disruption of host–microbe homeostasis and induces population changes in the 
subgingival biofilm, driving inflammatory periodontal diseases47,48,108. Previous 
work in our group has shown that Pg adherence to streptococci is driven by the 
interaction of the minor fimbrial antigen (Mfa) of Pg and the streptococcal antigen 
I/II (AgI/II)109,110. From these studies, a peptide (designated BAR), was developed 
that potently inhibits Pg/Sg adherence in vitro and reduces Pg virulence in a mouse 
model of periodontitis111-113. While efficacious, one of the challenges to free BAR 
administration is that it provides relatively transient inhibition of Pg in the oral 
cavity. Moreover, to treat established biofilms, relative to initial biofilm formation, 
higher concentrations of BAR are required. 
Polymeric delivery vehicles provide one option to address these challenges, 
by offering prolonged and targeted delivery of active agents. In particular, for 
application to the oral cavity, polymeric nanoparticles are easy to fabricate and 
produce stable formulations. From a delivery perspective, polymeric NPs may offer 
rapid degradation in the acidic environment of the oral cavity, while providing 
mucoadhesive properties due to the electrostatic interactions between NPs and 
gingival epithelium114-116. Furthermore, for more labile molecules like biologics, 
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polymers have the potential to protect the functionality of the active agent and 
provide tunable release and prolonged delivery, while enabling localization of the 
active agent to target sites115,117. In addition polymeric NPs may offer a safer and 
more biocompatible delivery method, relative to currently applied metallic NPs that 
exhibit broad antimicrobial effect118,119.  
Previous work in our groups has demonstrated that NPs surface-modified 
with BAR peptide more potently inhibit Pg adherence to Sg, relative to an 
equimolar administration of free BAR peptide in vitro95. This increased potency 
was attributed to a higher localized dose of BAR, facilitating multivalent interactions 
with Pg. While surface-modified NPs provide targeting efficacy, a method of 
delivering high concentrations of BAR for prolonged duration has not been 
investigated. In this study, we sought to develop a formulation that encapsulates 
and prolongs the delivery of BAR, for durations relevant to oral delivery. BAR-
encapsulated PLGA NPs were characterized and evaluated in two-species biofilm 
inhibition and disruption models. In addition, the kinetics of BAR-encapsulated, 
relative to BAR surface-modified NPs were assessed in a two-species model.  
Materials and Methods 
Peptide Synthesis 
 BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen 
I/II) protein sequence of Sg (NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-
COOH)112. To enable peptide quantification and detection, the epsilon amine of 
the underlined lysine residue of BAR was covalently reacted with 6-
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carboxyfluorescein to produce fluorescent BAR (F-BAR). Both unlabeled and 
labeled peptides were synthesized by BioSynthesis, Inc. (Lewisville, TX) and 
obtained with greater than 90% purity.  
BAR-Encapsulated and BAR Surface-Modified Nanoparticle Synthesis 
BAR and F-BAR encapsulated poly(lactic-co-glycolic acid) PLGA and 
methoxy-polyethylene glycol (mPEG-PLGA) NPs were synthesized using a 
double-emulsion technique89,120. Briefly, BAR was encapsulated in PLGA 
carboxyl-terminated polymer (0.55–0.75 dL/g; LACTEL®; DURECT Corporation, 
Cupertino, CA, USA) or mPEG-PLGA (Mw ~5,000:55,000 Da; PolySciTech®; 
Akina, Inc., IN, USA) using laboratory facilities (Figure 2.1). One hundred 
milligrams of PLGA or mPEG-PLGA was dissolved in 2 mL methylene chloride 
(DCM) overnight. The next day, BAR was dissolved in 200 μL Tris EDTA (TE) 
buffer at a concentration of 43 µg BAR/mg PLGA. The resulting PLGA/DCM 
solution was vortexed while adding 200 μL of BAR peptide solution dropwise, and 
the mixture was ultrasonicated. Next, 2 mL of the PLGA/DCM/BAR solution was 
added dropwise to 2 mL of 5% (w/v) polyvinyl alcohol (PVA) while vortexing and 
was subsequently sonicated. The NP solution was added to 50 mL of 0.3% PVA 
for 3 hr to evaporate residual DCM. After evaporation, the NP solution was 
centrifuged at 13,000 rpm at 4°C and washed with distilled water twice. F-BAR 
encapsulated NPs were synthesized similarly, but were protected from light to 
avoid photo bleaching.  
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BAR surface-modified NPs were synthesized similarly as above using a 
previously described double-emulsion technique (Figure 2.2)88,121,122. Briefly, the 
5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 5 mg/mL avidin-
palmitate and the 2 mL PLGA/DCM solution was added dropwise to 4 mL 
PVA/avidin-palmitate while vortexing. After the first wash, the supernatant was 
discarded and the pelleted NPs were resuspended in 10 mL PBS for 30 min on a 
benchtop rotator, with biotinylated BAR peptide at a molar ratio of 3:1 BAR:avidin 
(18.5 nmol/mg) in PBS. After conjugation, the NPs were washed two times with 
distilled water by centrifugation at 13,000 rpm at 4°C. After washing, both BAR-
encapsulated and BAR surface-modified NPs, were suspended in 5 mL of distilled 
water, frozen at -80°C, and lyophilized. 
 







Figure 2.2 Schematic representation of BAR surface-modified NP synthesis. 
 
NP Characterization: NP Morphology, Size, BAR Loading, Controlled 
Release 
 Unhydrated NP morphology, diameter, and size distribution were 
determined by analyzing scanning electron microscopy (SEM) images with NIH 
ImageJ software (version 1.5a, imageJ.nih.gov). Dynamic light scattering and zeta 
potential analyses were performed on hydrated NPs to determine the 
hydrodynamic diameter and surface charge (Malvern, Malvern, UK). To determine 
BAR loading and encapsulation efficiency (EE), NPs were dissolved in dimethyl 
sulfoxide (DMSO). The quantity of extracted F-BAR was determined by measuring 
fluorescence (488/518 nm excitation/emission). For BAR-encapsulated NPs, in 
vitro release was measured by gentle agitation of NPs in phosphate buffered saline 
(PBS, pH 7.4) at 37°C. At fixed time points (1, 2, 4, 8, 24, 48 hr), samples were 




Growth of Bacterial Strains 
 Pg ATCC33277 was grown in Trypticase soy broth (Difco Laboratories Inc., 
Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL 
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under 
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently 
inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aero-
bically without shaking in brain-heart infusion broth (Difco Laboratories Inc.) 
supplemented with 1% yeast extract for 16 hr at 37°C. 
Biofilm Inhibition Assay  
 To assess the effectiveness of BAR-encapsulated NPs to prevent the 
interaction of Pg with Sg, Sg was harvested from culture and labeled with 20 µL of 
5 mg/mL hexidium iodide for 15 min at room temperature. Following incubation, 
cells were centrifuged to remove unbound fluorescent dye. Subsequently, the 
bacterial concentration was measured by the O.D. at 600 nm from twenty-fold 
diluted cultures of Sg. The optical density of Sg cells was adjusted to 0.8 (1 x 109 
CFU/mL) to obtain uniformity between cell counts in each well. After adjusting the 
optical density, 1 mL of Sg cells was added to each well of 12-well culture plates 
containing a sterilized micro-coverslip. The cell culture plates were wrapped in 
aluminum foil to protect the labeled cells from light and placed on a rocker platform 
in the anaerobic chamber for 24 hr. 
 Pg cultures were optimized using a similar approach, utilizing a different 
fluorescent label (20 µL of 4 mg/mL carboxyfluorescein–succinylester). Pg was 
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incubated with the fluorescent dye for 30 min on a rocker platform and protected 
from light. The same procedures were followed as performed with Sg to determine 
cell concentration, with slight adaptations. The optical density of Pg was adjusted 
from 0.8 to 0.4 O.D. (5 x 107 CFU/mL) by diluting Pg cultures with an equal volume 
of BAR NPs or free BAR. The final concentration of BAR NPs or free BAR ranged 
from 0.3-3 µM based on the previously determined IC50 of free BAR (1.3 µM). Pg 
was incubated with BAR NPs or free BAR at 25°C for 30 min before transferring to 
wells containing Sg.  
 Plates containing Pg and Sg were subsequently incubated for 24 hr at 37°C 
in anaerobic conditions95. The following day, the supernatant was removed and 
cells were washed with PBS. Adherent cells were fixed with 4% (w/v) 
paraformaldehyde and the cover glass was mounted on a glass slide. Biofilms 
were visualized using a Leica SP8 confocal microscope (Leica Microsystems Inc., 
Buffalo Grove, IL) under 60x magnification. Background noise was minimized 
using software provided with the Leica SP8 and three-dimensional z-stack biofilm 
images were obtained from 30 randomly chosen frames using a z-step size of 0.7 
μm. Images were analyzed with Volocity image analysis software (version 6.3; 
Perkin Elmer, Waltham, MA, USA) to determine the ratio of green to red 
fluorescence (GR), representing Pg and Sg, respectively. Control samples were 
used to subtract background levels of auto-fluorescence. Briefly, triplicate samples 
of Sg alone were immobilized without Pg or BAR in 12-well culture plates and the 
same procedures for dual-species biofilm were followed. Sg-only coverslips were 
visualized and images were analyzed using the previously mentioned approach. 
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GR background was subtracted using the following formula: GR sample or control 
- GR Sg-only. Each treatment group (BAR NPs or free BAR) was analyzed in 
triplicate and three independent frames were measured for each well. The mean 
and variation (SD) between samples were determined using analysis of variance 
(ANOVA) and differences were considered to be statistically significant when p < 
0.05. The percent inhibition of Pg adherence was calculated with the following 
formula: GR sample/GR control.  
Biofilm Disruption Assay 
 The same procedures utilized in the inhibition assay were followed, except 
Pg was allowed to adhere to streptococci in the absence of BAR peptide or BAR 
NPs to demonstrate the ability of BAR-encapsulated NPs to disrupt or “treat” pre-
established biofilms. The resulting Pg/Sg biofilms were then treated for 3 hr with 
free BAR or BAR-encapsulated NPs at various concentrations and processed and 
analyzed as described above. 
Inhibitory Kinetics of BAR Released from BAR-Encapsulated NPs 
 Due to the similar release properties of BAR from PLGA and mPEG-PLGA 
NPs, PLGA NPs were selected to further assess the ability of NPs to release 
therapeutically relevant concentrations of BAR at different time points. PLGA BAR 
NPs (1.3 µM) were incubated with gentle agitation in PBS (pH 7.4) at 37°C. After 
1, 2, 4 and 8 hr, the NP suspension was centrifuged, and the supernatant was 
collected for biofilm experiments. The NPs were re-suspended with new PBS. Pg 
was incubated with BAR NP eluate for 30 minutes, and subsequently transferred 
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to a well containing an Sg biofilm. The same biofilm inhibition assay procedure 
detailed above was used to visualize and analyze the samples. 
Time-Dependent Comparison between Free BAR, BAR-Encapsulated, and 
BAR Surface-Modified NPs 
 In addition to delivering high concentrations of BAR during the time frame 
of interest, the temporal evaluation of BAR activity against established biofilms was 
evaluated and compared. Both BAR-encapsulated and BAR surface-modified NPs 
were assessed due to their previously demonstrated efficacy. Pg was allowed to 
adhere to streptococci in the absence of peptide, then BAR (3 µM), BAR-
encapsulated, and BAR surface-modified NPs (1.3 and 3 µM) were applied to the 
biofilms. The biofilms were assessed 1, 2, and 3 hr post-administration and 
visualized as described above. 
Results 
Nanoparticle Characterization  
The morphology, size, and zeta potential of BAR PLGA and mPEG-PLGA 
NPs were determined. The morphologies of BAR-encapsulated PLGA and mPEG-
PLGA NPs are shown in Figure 2.3. Both PLGA and mPEG-PLGA NPs 
demonstrated spherical morphology with average unhydrated diameters of 227.5 
± 23.0 nm and 243.1 ± 31.2 nm respectively (Table 2.1). In comparison, the 
average hydrated diameters of PLGA and mPEG-PLGA NPs were 234.4 ± 19.2 
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nm and 278.9 ± 13.8 nm, respectively. PLGA and mPEG-PLGA NPs had zeta 
potentials of -13.1± 0.4 mV and -5.9 ± 0.1 mV. 











PLGA NPs 227.5 ± 23.0 234.4 ± 19.2 -13.1 ± 0.4 
mPEG-PLGA NPs 243.1 ± 31.2 278.9 ± 13.8 -5.9 ± 0.1 
 
 
Figure 2.3 SEM images of BAR-encapsulated (A) PLGA NPs and (B) mPEG-
PLGA NPs. Scale bars represent 1 µm. 
Quantification of BAR Loading and Release 
The loading of BAR peptide in PLGA and mPEG-PLGA NPs was 
determined using fluorescence spectroscopy, and the fluorescence was compared 
to a known standard of F-BAR. Loading experiments demonstrated that both PLGA 
and mPEG-PLGA NPs highly encapsulated BAR with 19.0 ± 0.1 and 16.1 ± 0.2 µg 
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of BAR per mg of NP, respectively, corresponding to encapsulation efficiencies of 
44 and 37% (Table 2.2). 








PLGA NPs 43 19.0 ± 0.1 44.2 
mPEG-PLGA NPs 43 16.1 ± 0.2 37.3 
 
To assess BAR release from the NPs, the fluorescence of supernatant from 
1, 2, 4, 8, 24, 48 hr release time points was measured and compared to a known 
standard of F-BAR in PBS. Release experiments demonstrated that 47% of 
encapsulated BAR (10.3 µg/mg) was released from PLGA NPs, while 56% of BAR 






Figure 2.4 Cumulative release of BAR as a function of mass (µg BAR per mg NP, 
open symbols) and percent of total BAR loaded (closed symbols) over 48 hr. 
Inhibition (or Prevention) of Pg/Sg Biofilm Formation 
BAR-encapsulated PLGA and mPEG-PLGA NPs were functionally 
evaluated to determine their potential to inhibit Pg adherence to Sg after 24 hr, 
relative to free BAR. As shown in Figure 2.5 and 2.6, Pg adherence was 
significantly reduced in the presence of BAR-encapsulated PLGA and mPEG-
PLGA NPs. Adherence was inhibited by 39% at the lowest administered 
concentration (0.3 µM), 59% at 0.7 µM, and reached maximum inhibition (94%) at 
the highest concentration of PLGA NPs tested (3 µM). Similar inhibitory results 
were observed for mPEG-PLGA NPs, where Pg /Sg biofilm formation was inhibited 
by 37%, 55%, and 92% at concentrations of 0.3 µM, 0.7 µM and 3 µM respectively. 
The ability of BAR-encapsulated NPs to inhibit biofilm formation was dose-
dependent (IC50 = 0.70 ± 0.18 µM) with no statistically significant differences 
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between PGLA and mPEG-PLGA BAR-encapsulated NPs (p > 0.05). Moreover 
these results indicate that a lower concentration of BAR is required if incorporated 
within NPs, relative to free BAR administration (IC50 =1.35 ± 0.12 µM) (Figure 
2.5). 
 
Figure 2.5 BAR-encapsulated PLGA NPs prevent Pg adherence to Sg. Biofilms 
were visualized with confocal microscopy and the ratio of green (Pg) to red (Sg) 
fluorescence in z-stack images was determined using Volocity image analysis 




Figure 2.6 BAR-encapsulated mPEG-PLGA NPs prevent Pg adherence to Sg. 
Biofilms were visualized with confocal microscopy and the ratio of green (Pg) to 
red (Sg) fluorescence in z-stack images was determined using Volocity image 
analysis software. Each grid = 21 µm. 
Disruption (or Treatment) of Pg/Sg Biofilms 
To determine whether BAR peptide is capable of disrupting pre-existing 
Pg/Sg biofilms, dual-species biofilms were formed in PBS in the absence of BAR 
peptide for 24 hr, and were subsequently incubated for 3 hr with BAR-
encapsulated PLGA or mPEG-PLGA NPs. Various molar concentrations of BAR 
NPs ranging from 0.3 to 3 µM were tested. The biofilms were visualized and the 
percent inhibition was calculated as described above. As shown in Figure 2.7 and 
2.8, BAR-encapsulated PLGA and mPEG-PLGA NPs disrupted pre-existing dual-
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species biofilms by ~25% with the lowest administered concentration (0.3 µM), 
40% with 0.7 µM, and 85% with 3 µM of BAR-encapsulated PLGA NPs. Similar 
trends were observed for the disruption of pre-existing biofilms with 0.3, 0.7, and 
3 µM mPEG-PLGA NPs (20%, 38%, and 80% disrupted). Overall the IC50 values 
of PLGA and mPEG-PLGA (1.35 ± 0.12 µM) NPs for biofilm disruption were not 
statistically significant (p > 0.05, Figure 2.9); demonstrating statistically significant 
improvements in efficacy relative to free BAR (p < 0.05).  
 
Figure 2.7 BAR-encapsulated PLGA NPs disrupt pre-established Pg-Sg biofilms. 
Biofilms were visualized with confocal microscopy and the ratio of green (Pg) to 
red (Sg) fluorescence in z-stack images was determined using Volocity image 




Figure 2.8 BAR-encapsulated mPEG-PLGA NPs disrupt pre-established Pg-Sg 
biofilms. Biofilms were visualized with confocal microscopy and the ratio of green 
(Pg) to red (Sg) fluorescence in z-stack images was determined using Volocity 






Figure 2.9 Comparison of the concentration of BAR-encapsulated PLGA and 
mPEG-PLGA NPs needed to (A) inhibit or (B) disrupt Pg/Sg biofilms. 
Inhibitory Activity of BAR Released from BAR-Encapsulated NPs 
To determine the inhibitory potential of BAR-encapsulated NPs, as a 
function of release duration, streptococcal cells were immobilized and Pg was 
incubated with eluate released from 1.3 µM BAR-encapsulated PLGA NPs at 1, 2, 
4, and 8 hr. BAR-encapsulated PLGA NPs were selected due to their similar 
release and inhibitory properties, relative to mPEG-PLGA NPs. As shown in 
Figure 2.10, BAR released during the first two hours, inhibited biofilm formation 
(68% and 32%, respectively) when compared to the control untreated biofilm, 
whereas BAR released after 4 and 8 hr provided less  inhibitory activity against  
biofilm formation (25% for both time points). These results indicate that BAR-




Figure 2.10 BAR-encapsulated PLGA NPs inhibit Pg adherence to Sg after 
different durations of release. Biofilms were visualized with confocal microscopy 
and the ratio of green (Pg) to red (Sg) fluorescence in z-stack images was 
determined using Volocity software. Each grid = 21 µm. 
Time-Dependent Comparison of Free BAR, BAR-Encapsulated, and BAR 
Surface-Modified NP Biofilm Disruption 
Previous studies demonstrated that BAR surface-modified PLGA NPs 
potently disrupt pre-established Pg/Sg biofilms95. To compare the temporal effect 
resulting from the administration of the newly formulated BAR-encapsulated NPs, 
relative to free BAR or previously tested BAR surface-modified NPs, two 
concentrations of BAR-encapsulated and BAR surface-modified PLGA NPs were 
compared with free BAR after 1, 2, and 3 hr administration to pre-established 
biofilms. As shown in Table 2.3 and Figure 2.11, free BAR (3 µM) minimally 
disrupted pre-existing biofilms during the first hour of application (23%), and 
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demonstrated a slight increase in disruption after two hours (44%).  After 3 hr, free 
BAR (3 µM) disrupted 69% of the pre-existing biofilm. In comparison, 
administration of the same equimolar concentration of BAR-encapsulated NPs (1.3 
and 3 µM) disrupted the established biofilm during the first hour of exposure by 
32% and 38%, respectively and demonstrated even more potent disruption (47% 
and 52%) after two hours. The maximum disruption for 1.3 and 3 µM doses (66% 
and 77%, respectively) was achieved after 3 hr exposure to biofilms. 
Comparatively, both 1.3 and 3 µM BAR surface-modified NPs disrupted pre-
existing biofilms within one hour by 43% and 49%, respectively, and induced more 
potent biofilm disruption (59% and 69%) after 2 hr exposure, demonstrating 
statistically significant disruption, relative to disruption induced by free BAR 
peptide. The highest levels of disruption (71% and 83% respectively) were 
achieved after 3 hr BAR surface-modified NP administration. Overall, BAR surface-
modified NPs were statistically more effective than free BAR (p <0.05) in disrupting 
established biofilms after 1, 2, and 3 hr administration. However, no statistical 
differences were observed for BAR-encapsulated NPs (p > 0.05), relative to BAR 




Figure 2.11 Disruption of established Pg/Sg biofilms after different exposure times 
to BAR surface-modified NPs, BAR-encapsulated NPs and free BAR. Biofilms 
were visualized with confocal microscopy and the ratio of green (Pg) to red (Sg) 
fluorescence in z-stack images was determined using Volocity software. Each grid 













NPs (1.3 µM) 
BAR-mod 
NPs (3 µM) 
BAR-encap 
NPs (1.3 µM) 
BAR-encap 
NPs (3 µM) 
1 22.6 ± 0.2 43.4 ± 0.2 48.9 ± 0.1 32.3 ± 0.1 37.7 ± 0.1 
2 44.4 ± 0.2 59.2 ± 0.1 68.7 ± 0.1 46.6 ± 0.2 52.4 ± 0.2 
3 69.0 ± 0.0 71.2 ± 0.1 83.4 ± 0.0 66.1 ± 0.1 77.0 ± 0.0 
 
Discussion  
Porphyromonas gingivalis has been identified as a “keystone” pathogen 
involved in the initiation and progression of periodontal inflammatory disease, by 
disrupting host-microbe homeostasis and inducing population changes in the 
subgingival biofilm. This disruption and colonization is initially prompted by the 
association of Pg with oral streptococci in the supragingival niche, and is thus an 
ideal target for therapeutic intervention9. Previous studies have shown that BAR 
peptide inhibits biofilm formation by Pg and Sg in vitro and reduces the virulence 
of Pg in a murine model of infection15,17. While efficacious, BAR effectiveness was 
limited by the duration of exposure within the oral cavity, and necessitated a higher 
concentration to disrupt previously established biofilms15, 17. In previous work we 
sought to address these challenges by synthesizing BAR surface-modified NPs to 
multivalently inhibit biofilm formation95. The goal of this study was to develop, 
37 
 
characterize, and compare BAR-encapsulated NPs that release BAR within a time 
frame relevant to delivery in the oral cavity. 
Nanoparticle characterization revealed that PLGA and mPEG-PLGA BAR-
encapsulated NPs exhibited spherical morphologies and average particle 
diameters of 234.4 ± 19.2 nm and 278.9 ± 13.8 nm, with respective zeta potentials 
of -13.1 ± 0.4 mV and -5.9 ± 0.1 mV. These values are in agreement with expected 
values for these polymeric NPs89,120.  Both PLGA and mPEG-PLGA NPs were 
synthesized with 43 µg of BAR per mg NP, corresponding to loading 
concentrations deemed feasible for biofilm inhibition with free BAR111-113. PLGA 
and mPEG-PLGA NPs demonstrated relatively high peptide loading with 19.0 ± 
0.1 and 16.1 ± 0.2 µg BAR per mg of NP respectively.  
In addition to high loading, PLGA and mPEG-PLGA NPs released 40% and 
48% of BAR within the first 4 hr, with no statistically significant differences between 
release profiles. The NP formulations were designed to achieve therapeutic 
concentrations of BAR in the oral cavity for a minimum of 2 hr. This initial window 
of 2 hr release was targeted as we envision formulating NPs in a mouth rinse or 
toothpaste product. Ideally, in future formulations, we seek to tailor the release of 
peptide for up to 12 hr since we envision these formulations may be applied once 
or twice daily, to exert immediate effect over a number of hours.  
To assess the functionality of BAR-NPs, the inhibition and disruption 
concentrations of BAR-encapsulated PLGA and mPEG-PLGA NPs were 
determined against dual-species biofilms. As shown in Figures 2.5 through 2.8, 
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BAR NPs demonstrated potent inhibition and disruption with IC50s = 0.7 µM and 
1.3 µM, respectively, with negligible differences observed between PLGA and 
mPEG-PLGA NPs. To explore the temporal effect of BAR released from PLGA 
NPs on biofilm inhibition (prevention) in greater depth, the efficacy of BAR-
encapsulated NPs was assessed in a dual-species biofilm after 1, 2, 4 and 8 hr 
post-application. Sufficient BAR release was achieved, relating to inhibitory 
concentrations of 1.3 µM during the first 4 hr of administration (Figure 2.10). 
Moreover, the temporal dependence of free BAR, BAR-encapsulated, and BAR 
surface-modified NPs to disrupt pre-established biofilms (treatment) was 
measured after 1, 2, and 3 hr application. As shown in Figure 2.11 and Table 2.3, 
BAR-encapsulated and BAR surface-modified NPs achieved moderate biofilm 
inhibition within 1 hr in a dose-dependent manner; however, similar concentrations 
of free BAR required prolonged exposure of up to 3 hr to achieve more potent 
effect. These results demonstrate that BAR-encapsulated NPs provide a feasible 
alternative to free BAR and BAR surface-modified NPs to target dual-species oral 
biofilms and provide rapid onset of action. Together, these studies indicate that 
BAR-encapsulated NPs may serve as a short-term delivery formulation to enhance 
BAR delivery and potency in the oral cavity. Moreover, by encapsulating versus 
surface-modifying NPs with BAR, these NPs may offer the potential to specifically 
target NPs with modifications that can complement BAR activity to engage with 
these or other bacterial species in future work. 
To date, a variety of polymeric nanoparticle formulations have been 
developed for oral delivery; however, these vehicles have primarily focused on the 
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delivery of non-specific active agents such as antibiotics86,90,91,94,123-128. Antibiotics 
such as chlorhexidine123,124, minocycline86,94, clarithromycin126, vancomycin125, 
doxycycline127, and tetracycline90,91,128 are among the antibiotics that have been 
incorporated into a variety of polymeric vehicles86,90,94,124-127 to provide sustained-
delivery, prolong activity, exert antibacterial activity, and decrease antibiotic 
cytotoxicity86,90,94,124-127. Yet, despite antibiotic choice, primary concerns of 
antibacterial resistance and cytotoxicity remain90,123,124. While chitosan and PLGA 
NPs that encapsulated chlorhexidine dihydrochloride (CHX) demonstrated strong 
adherence to tooth surfaces and sustained-release for 48 hr in neutral pH 
conditions, moderate cytotoxicity due to CHX was observed in human gingival 
fibroblasts124.  Similar studies seeking to ameliorate periodontal infection caused 
by A. actinomycetemcomitans and P. nigrescens with PLGA lovastatin-chitosan-
tetracycline NPs demonstrated potent inhibition up to one week after 
administration. However, significantly elevated alkaline phosphatase was 
observed in cells treated with 0.1% or 0.3% tetracycline-loaded nanoparticles on 
days 7 and 990. Overall, these studies have shown that delivery vehicles have the 
potential to increase antibiotic effectiveness by decreasing the concentration 
required. However, bacterial resistance, non-specific targeting, and cytotoxicity 
concerns with chronic use suggest that the development of more specifically acting 
active agents will offer safer alternatives for biofilm inhibition.  
More recently, specifically targeted biological agents have been 
investigated to treat periodontal diseases. Delivery of thyA gene129, Punica 
granatum extract130, H. madagascariensis leaf extract131, miR-146a132, and the 
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anti-inflammatory agent 15d-PGJ2133 have been investigated to vaccinate against 
and target periodontal diseases. Recent work assessed the delivery of an oral 
vaccine comprised of an auxotrophic complementation of the thyA gene to 
produce an immune response against Sg. Although this study demonstrated 
promise utilizing Sg as a live oral vaccine, to date there are few formulations 
available to localize or sustain biologic administration to the oral cavity129. In other 
work, PLGA NPs encapsulating a novel anti-inflammatory agent (15d-PGJ2), 
demonstrated promise in reducing inflammatory response and bone resorption in 
mouse model of periodontitis after daily administration133, demonstrating the 
feasibility of combined biologic and delivery vehicle against oral pathogens.  
Despite this recent progress in the delivery of biological agents for oral 
applications, currently few biological agents in combination with delivery vehicles 
have been developed to inhibit keystone-specific interactions during the initial 
stages of periodontal disease95.  
In addition to progress in the development of vehicles to encapsulate 
antibiotic and biological agents in polymeric delivery vehicles, polymeric platforms 
have also been surface-modified with a variety of molecules including RGD94, 
chitosan124,126, tertiary amines bearing two t-cinnamaldehyde substituents134, 
dimethyl-octyl ammonium134, and BAR peptide95 to increase the mucoadhesivity 
(and in the latter case, specificity) of oral delivery formulations. 
  A variety of polymers have been modified with biological ligands to impart 
enhanced therapeutic effect94,95.  As one example, the delivery of antibiotic 
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minocycline-loaded poly(ethylene glycol)–poly(lactic acid) (PEG–PLA) 
nanoparticles have targeted oral epithelial cells by surface-modification with RGD 
peptides. Surface-modification of PEG-PLA NPs increased epithelial cell 
attachment and maintained effective drug concentrations in gingival fluid for more 
than two weeks in vivo, relative to unmodified minocycline NPs. Similarly, chitosan-
modified polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer (Soluplus) and poly-(DL-lactide-co-glycolide) nanoparticles loaded with 
clarithromycin, increased antibacterial efficacy and provided sustained-release 
against oral biofilms126. Although this study demonstrated effective treatment of 
periodontitis, the limitations of antibiotic delivery still pose challenges94. Surface 
modification of nanoparticles has imparted new attributes to target active agents 
to oral-specific niches. We expect that combining our current work, with surface 
functionalization demonstrated in our previous study95, may confer additional 
advantages in targeting keystone species by providing prevention and treatment 
via adhesion and a localized release-mediated platform.  
Taken together, our results demonstrate that BAR-encapsulated NPs 
achieve more potent inhibition and disruption than equimolar free BAR 
administration. We believe that incorporation of BAR peptide in NPs provides 
gradual release of BAR peptide, while BAR-modification offers a platform to 
provide a higher localized concentration of BAR in the oral cavity via multivalent 
interactions. BAR-encapsulated NPs offer a platform to improve efficacy, and 
potentially longevity in the oral cavity compared to the transient activity of free 
BAR. These experimental results will be helpful in developing NPs in therapeutic 
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formulations such as toothpaste, mouth rinse or chewing gum. Future studies may 
focus on developing blended polymeric NPs to more gradually release inhibitory 
concentrations for 8-12 hr. Moreover, combining this platform with surface 
functionality to provide mucoadhesive or specific interactions with gingival tissue 
may be pursued to enhance the targeting potential. Ongoing and future work in our 
groups seeks to assess the efficacy of both BAR-modified and BAR-encapsulated 













FUNCTIONAL ASSESSMENT OF PEPTIDE-MODIFIED PLGA 
NANOPARTICLES AGAINST ORAL BIOFILMS IN A MURINE MODEL OF 
PERIODONTITIS 
Introduction   
 The most common and currently employed periodontal treatments consist 
of physical methods such as scaling and root planing to remove the oral biofilm, 
followed by antibiotic therapy. However, variation in patient response and the 
immediate reformation of the oral biofilm post-removal can promote disease 
recurrence. In addition to the challenges associated with mechanical debridement, 
the administration of local and systemic antibiotics can enhance opportunistic 
fungal infections, potential allergic reactions, or the emergence of antibacterial 
resistant species. Moreover, current antibiotics may non-specifically disrupt 
microbial homeostasis by killing commensal organisms, and often high, frequently 
administered doses are required to penetrate periodontal biofilms35,37,107. Given 
these challenges, the development of more specific agents targeting periodontal 
pathogens has the potential to offer safer and more effective alternatives against 




While several studies have investigated natural and synthetic biologics 
against oral inflammation and biofilms, including Punica granatum extract130  H. 
madagascariensis leaf extract131, miR-146a132, and the anti-inflammatory agent 
15d-PGJ2133, our approach has been to target the specific interaction between Pg 
and oral streptococci that contributes to the initial colonization of the oral cavity 
leading to the development of periodontal disease111.  
 Previous work in our group has shown that Pg adherence to streptococci is 
driven by the interaction of the minor fimbrial antigen (Mfa) of Pg with streptococcal 
antigen (e.g., SspB) I/II (AgI/II)109,110. SspB polypeptide is a multifunctional surface 
protein of Sgi and is a member of antigen I/II complex that is expressed by nearly 
all streptococci that inhabit the oral cavity. SspB is 1,500 residues in length and 
includes seven structural domains that are effectively maintained in all antigen I/II 
polypeptides. Previous studies in our group have shown that the region 
encompassing residues 1167 to 1250 of SspB (designated BAR) was required for 
the in vitro adherence of Pg to Sg cells. From these studies, a peptide (designated 
BAR), was developed that potently inhibited Pg adherence to streptococci in vitro 
and reduced Pg virulence in a mouse model of periodontitis. However, while BAR 
inhibited the initial formation of Pg/streptococcal biofilms, much higher 
concentrations of peptide were required to disrupt an established biofilm. In 
addition, disruption of more complex three-species biofilms containing a bridging 
organism such as Fusobacterium nucleatum also required higher concentration 
and prolonged exposure to BAR. 
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 Currently, a variety of localized delivery approaches, including gels, 
implants, fibers, and films are used to deliver antibiotics. These formulations are 
often administered following the scaling process to retain antibiotics for prolonged 
duration in periodontal pockets. However, non-degradable implants such as nylon 
fibers135, and acrylic and ethyl cellulose strips136,137 require surgical removal, while 
burst release of active agents is often observed after the administration of films 
and gels94,138. Recently, polymeric nanoparticles have been investigated as a 
potential alternative to deliver active agents, due to their proven safety and 
biocompatibility. Moreover, in contrast to the ubiquitous activity of metallic NPs 
with inherent antimicrobial efficiency139,140, FDA-approved polymers such as 
poly(lactic-co-glycolic) acid (PLGA), have demonstrated biocompatibility and 
flexible tuning of physical properties, enabling tailored drug release and favorable 
dosing profiles115. In addition, polymer NPs have the ability to impart 
mucoadhesive properties due to the electrostatic interactions between NPs and 
gingival epithelium114-116. While a variety of polymer types can promote 
mucoadhesion, NPs synthesized from commonly used polymers, such as PLGA, 
may achieve mucoadhesion via hydrogen bonding, polymer entanglement with 
mucins, hydrophobic interactions, or a combination of these mechanisms141,142. 
Furthermore, NP transport and internalization through the epithelium is dependent 
on particle size, surface charge, polymer hydrophobicity, mucoadhesivity, and the 
presence or absence of surface ligands like chitosan or PEG116,132,141. From a 
fabrication perspective, PLGA NPs are easily synthesized and provide long lasting 
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formulations that can protect active agents, especially more labile biological 
agents, thereby maintaining their functional activity.  
Given the attributes of PLGA NPs, we sought to address some of the 
delivery challenges confronting free BAR, including the relatively transient 
inhibition of Pg in the oral cavity and higher localized doses of BAR required to 
disrupt established biofilm111-113,143. Multivalency is one option to improve the 
binding of BAR by enhancing the avidity and decreasing the detachment rate from 
Pg95,144,145. Previous studies have demonstrated that multivalently targeted NPs 
can improve binding, increase localized concentration and decrease the effective 
therapeutic doses and frequencies94,95,121,134,146. Previous work from our groups 
demonstrated that BAR-modified NPs (BAR-NPs) delivered a high localized 
concentration of BAR peptide and improved the in vitro effectiveness of BAR 
through multivalent interactions with Pg, relative to free BAR95. Thus, we 
hypothesized that conjugating BAR to the NP surface may similarly decrease the 
therapeutic dose of BAR required to inhibit biofilm formation in vivo through 
multivalent binding to Pg, more effectively inhibiting oral biofilm formation95,134. For 
oral administration, we administrated free BAR and BAR-modified NP with 2% 
carboxymethylcellulose to test BAR-NPs against the “best” case adhesive 
formulations to improve retention in the oral cavity and to target Pg. In future work, 
we propose to incorporate BAR-NPs in a mouthwash or gel formulation to be 
applied twice daily. Here our goal was to advance our previous in vitro work to 
assess the in vivo efficacy and safety of BAR-modified NPs in a murine model of 
periodontitis and in gingival and erythrocytic cell lines.  
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Materials and Methods 
Peptide Synthesis 
 BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen 
I/II) protein of Sg with the sequence NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-
COOH112. To facilitate conjugation of BAR to the NP surface, the peptide was 
synthesized with an N-terminal biotin. Biotinylated BAR was subsequently 
attached to NPs that had been modified with palmitylated avidin. To enable peptide 
quantification and detection, some preparations of BAR were modified such that 
the epsilon amine of the underlined lysine residue of BAR was covalently reacted 
with 6-carboxyfluorescein to produce fluorescent BAR (F-BAR). All preparations of 
peptides were synthesized by BioSynthesis, Inc. (Lewisville, TX) and were 
guaranteed to have greater than 90% purity via RP-HPLC analysis.  
BAR Surface-Modified Nanoparticle Synthesis 
 BAR surface-modified NPs were synthesized using a previously described 
single-emulsion technique88,121. PLGA with a 50:50 monomer ratio and 0.55–
0.75 dL/g inherent viscosity, was purchased from LACTEL®. Briefly, 100 mg PLGA 
was dissolved in 2 mL dichloromethane (DCM) overnight. The following day, 2 mL 
of a 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 5 mg/mL 
avidin-palmitate. The 2 mL PLGA/DCM solution was added dropwise to 4 mL 
PVA/avidin-palmitate solution while vortexing. The NP solution was added to 50 
mL of 0.3% PVA for 3 hr to evaporate residual DCM. After evaporation, the NP 
solution was centrifuged at 13,000 rpm (20,442 x g) at 4°C. Supernatant was 
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discarded, and the pelleted NPs were resuspended in 10 mL phosphate buffered 
saline (PBS) for 30 min on a benchtop rotator, with biotinylated BAR peptide at a 
molar ratio of 6:1 BAR:avidin (18 nmol/mg) in PBS. After conjugation, the NPs were 
washed two times with deionized water (diH2O) by centrifugation at 13,000 rpm 
(20,442 x g) at 4°C to obtain NPs with sizes less than ~200 nm. After washing, 
BAR surface-modified NPs were suspended in 5 mL of diH2O, frozen at -80°C, 
and lyophilized.  F-BAR-modified NPs were synthesized similarly, but were 
protected from light during synthesis. 
NP Characterization: NP Morphology, Size, BAR Conjugation 
 Unhydrated NP morphology, diameter, and size distribution were 
determined using scanning electron microscopy (SEM) (XL-30 ESEM-FEG SEM, 
FEI Company, USA). Lyophilized NPs were mounted on carbon tape and sputter 
coated with a thin layer of gold/palladium. Average diameters of 500 particles were 
determined from SEM images (n=3) using image analysis software (ImageJ, 
National Institutes of Health, version 1.5a, ImageJ.nih.gov). Dynamic light 
scattering and zeta potential analyses were performed to determine the 
hydrodynamic diameter and surface charge of hydrated NPs. The unhydrated and 
hydrated diameters of NPs are typically assessed to establish the size 
characteristics within different conditions of dry storage and more physiologically 
relevant aqueous environments. Briefly, a 1 mg/mL sample of BAR-modified PLGA 
NPs in diH2O was prepared. After vortexing and sonication, samples were diluted 
at a 1:50 ratio in diH2O. One mL was aliquoted to the cuvette for analysis [Malvern, 
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Malvern, UK (Zetasizer Nano ZS90), courtesy of Dr. Martin O’Toole, Univ. of 
Louisville] to measure dynamic light scattering and zeta potential with Zetasizer 
Nano software. Samples were run in triplicate, using a refractive index of 1.57 for 
PLGA, absorption coefficient of 1, and water refractive index of 1.33. The 
equations used by the Zetasizer to calculate nanoparticle size are shown in 
Supplementary Data. 
To measure the amount of BAR peptide that was conjugated to the NP 
surface, a fluorescence binding assay was conducted with F-BAR NPs.  After 
conjugation, NPs were centrifuged and washed twice with diH2O to remove 
unbound BAR from the formulated NPs. NPs were then suspended in 1X PBS to 
create a 1 mg/mL NP solution and the resulting samples were transferred to a 
microtiter plate in triplicate. Total NP-associated fluorescence was determined 
using Victor3 Multilabel spectrophotometer (488/518 nm excitation/emission), and 
peptide quantity was determined from a standard curve of known F-BAR 
concentrations95. The stability of the avidin palmitate interaction with the NP 
surface has been previously tested by assessing the release of avidin and 
biotinylated ligand from the NP surface with respect to time146,147. In addition, the 
functional stability of BAR-NPs was tested through in vitro inhibition assays against 
biofilms prior to these in vivo experiments95. 
Growth of Bacterial Strains 
 Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories 
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL 
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menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under 
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently 
inoculated and grown anaerobically for 48 hr at 37°C.  Sg DL-1 was cultured aero-
bically without shaking in brain-heart infusion broth (Difco Laboratories Inc.) 
supplemented with 1% yeast extract for 16 hr at 37°C111-113. 
In Vivo Model of Periodontitis 
 The protocols used for the study were approved by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Louisville, as described in 
the federal guidelines for the care and use of laboratory animals. Ten weeks-old 
specific-pathogen-free BALB/cByJ mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME) and housed in the University of Louisville Research 
Resource Center animal facility.  The mice were fed with Lab Diet 5001 meal 
(Purina Mills, LLC, Gray Summit, MO) during the entire experiment.  
 The oral infection of mice was performed as previously described113. A total 
of 8 mice per group were used per experiment. Animals were initially treated with 
sulfamethoxazole (MP Biomedical, Solon, OH) at a final concentration of (800 
µg/mL) and trimethoprim (Sigma, St. Louis, MO) at a final concentration of (400 
µg/mL) ad libitum for 10 days, every two days. Four days after the last antibiotic 
treatment, all groups of mice with the exception of the sham-infected control group 
were orally infected with 109 CFU of Sg cells suspended in 1 mL of 2% 
carboxymethylcellulose (CMC; MP Biomedical, Solon, OH) in sterile PBS using a 
2.25 mm feeding needle (Popper and Sons, Inc., New Hyde Park, NY). Sg was 
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administered five times in total, every two days. Sham-infected animals received 
CMC without bacteria. Following confirmation of Sg colonization by PCR, two 
groups of animals were infected five times with 107 CFU of Pg in CMC containing 
BAR (0.7 and 3.4 µM) at two day intervals and another group was infected five 
times with 107 CFU of Pg in CMC containing BAR-NPs (BAR concentration = 0.7 
µM) at two day intervals. Two additional groups of animals were infected either 
with Pg alone or Sg alone. After the infection process, all animals were 
subsequently rested for 47 days with daily observation to record death or sickness 
and then euthanized via CO2 asphyxiation. 
Infection Confirmation 
 Sg and Pg colonization were confirmed by collecting oral samples from the 
gingiva of the upper molars using a 15 cm sterile polyester-tipped applicator 
(Puritan Medical Products Co., Guilford, ME), 14 days after the last oral infection. 
Samples were then added to 10 mL of brain-heart infusion broth (Difco 
Laboratories Inc.) for streptococcal species enrichment and trypticase soy broth 
(Difco Laboratories Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast 
extract, 1 µg/mL menadione, and 5 µg/mL hemin to select for Pg. Samples were 
incubated at 37°C for 24 hr under anaerobic conditions. The resulting cells were 





Determination of Maxillary Alveolar Bone Loss 
 Mouse skulls were autoclaved for 15 min to remove skin and muscles, and 
were subsequently soaked in 3% hydrogen peroxide overnight at room 
temperature to remove remaining muscle. Skulls were washed with diH2O and 
cleaned with a 1% bleach solution for 30 s, sonicated at 14 V for 1 min, and washed 
again with diH2O. To confirm skull cleaning, toothpaste was applied and brushed 
away, followed by immersion in a 1% bleach solution for 30 s and sonication (14 
V). To stain the skulls, skulls were immersed in 1% methylene blue for 15 s and 
rinsed with DI water to remove excess dye. The stained skulls were air-dried prior 
to alveolar bone loss measurements. Bone loss was assessed by measuring the 
distance between the alveolar bone crest (ABC) and the cemento-enamel junction 
(CEJ) at 7 sites on the buccal side of the right and left maxillary molars for a total 
of 14 measurements. This was accomplished using a dissecting microscope fitted 
with a video imaging marker measurement system (model VIA-170K; Fryer) at a 
total magnification of 40x113. Measurements were taken in millimeters. The 
average of the total bone loss for each mouse group was assessed and subtracted 
from the baseline bone loss observed in sham-infected mice. Statistical differences 
in bone loss were analyzed by ANOVA after passing Bartlett's and Brown-Forsythe 
tests for homogeneity of variances using GraphPad InStat (La Jolla, CA). A pair-
wise, parametric analysis of variance using a Bonferroni multiple comparison post-
test was used to determine the statistical difference among the individual mouse 




Samples of maxillary molar regions were dissected from each mouse, and 
then fixed in 4% paraformaldehyde overnight. Periodontal tissues were dehydrated 
by passing through ascending concentrations of ethanol then cleared in xylene 
and embedded in paraffin. Serial sections (5-6 μm) were cut and mounted on glass 
slides (Sigma, St. Louis, MO). Microscopic examination for slides was carried out 
after hematoxylin and eosin staining148. 
Immunofluorescence Assay  
An immunofluorescence assay was used to assess IL-17 expression in 
gingival sections. Tissue sections, 5-6 μm in thickness, were mounted on glass 
slides. Tissue sections were deparaffinized by immersion in xylol two times for 15 
min each, and rehydrated in absolute, 95% and 70% ethanol. Excess ethanol was 
removed then slides were placed in water. Antigen IL-17 was recovered by 
microwave heating in water and non-specific binding was blocked with 5% bovine 
serum albumin for 1 hr. Then, slides were incubated for 24 hr at 4˚C with IL-17A 
monoclonal antibody AlexaFluor 488 (eBioscience™), examined via confocal 
microscopy, and IL-17 immunofluorescence was quantified using Volocity 
software149. 
Tissue Culture 
Telomerase immortalized gingival keratinocytes (TIGKs) were grown on 24-
well collagen-coated plates (Becton Dickinson, Bedford, MA) and cultured using 
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DermaLife K Calcium Free Medium (LifeFactors®) supplemented with 
penicillin/streptomycin (100 U/mL final concentration; St. Louis, MO), recombinant 
human (rh) insulin (5 µg/mL), L-glutamine (6 mM), epinephrine (1 µM), apo-
transferrin (5 µg/mL), rh TGF-α (0.5 ng/ mL), extract PTM, hydrocortisone 
hemisuccinate (100 ng/mL), and calcium chloride (0.06 mM). The epithelial cells 
were incubated at 37°C in the presence of 5% CO2 for 6 days until they reached 
95% confluence. The cells were washed and administered media without 
antibiotics during toxicity testing. 
Determination of BAR and BAR-NP In Vitro Cytotoxicity 
Hemolytic Assay: A total of 250 µL of 1% sheep erythrocytes (Rockland Inc, 
Pennsylvania, USA) was suspended in sterile PBS containing 5% fetal bovine 
serum (FBS buffer). BAR-NPs or free BAR peptide were suspended in FBS at 
concentrations of 1.3 and 3.4 µM (the maximum concentrations used in in vitro and 
in vivo studies) and were added to the erythrocyte suspension. The mixtures were 
incubated at 37°C for 3 hr. After centrifugation (3,500 x g), hemoglobin released 
due to cell lysis was analyzed by spectrophotometry at 541 nm. A positive control 
group was run in which PBS was replaced with diH2O.  
MTT Assay: TIGK cells were seeded in 12-well plates at a density of 6 x 104 cells 
in 1 mL media per well, and incubated for 24 hr to allow for 60–70% confluency 
and sufficient adhesion. Cells were treated with 1.3 or 3.4 µM of free BAR or BAR-
NPs. After 24 hr, 100 µL of MTT solution (10% of total volume) was added to the 
media of all samples. The solution was incubated at 37°C for 4 hr. After this period, 
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550 µL of lysis buffer (50% of total volume) was added to the media of each well 
and plates were incubated for overnight. The absorbance of each well was read at 
570 nm, and the sample absorbance was normalized to the absorbance of 
untreated cells (media only). Treatment with 10% DMSO media (100 µL DMSO in 
900 µL media) was used as a positive control for cell death. 
ATP Assay: Total ATP levels in cell culture were assessed by using the CellTiter-
Glo reagent (Promega, Madison WI), as described by the manufacturer. TIGK cells 
were seeded at a density of 6 x 104 cells in 1 mL media per well and incubated at 
37°C, 5% CO2 for 24 hr in a 12-well flat bottom plate.  Cells were then incubated 
with free BAR or BAR-NPs (1.3 or 3.4 µM) for 24 hr at 37°C in 5% CO2. Cells were 
then lysed with 500 µL of 0.1% Triton X-100 for 30 min at 37°C. The lysates were 
collected and centrifuged at 1,000 x g for 10 min at 4°C, and 50 µL of supernatant 
was mixed with 50 µL of CellTiter-Glo reagent. Samples were incubated at ambient 
temperature for 10 min in a black 96-well plate in the dark. Total luminescence was 
measured with a Victor 3 luminometer (Perkin-Elmer, Inc). Cells incubated with 1 
ng of staurosporine or with medium only served as positive and negative controls 
for cell death, respectively. 
LDH Assay: Cell membrane leakage was measured by the release of lactate 
dehydrogenase (LDH).  Extracellular LDH was quantified using a CytoTox96® non-
radioactive cytotoxicity assay (Promega, Madison WI) as described by the 
manufacturer. TIGK cells were plated at density of 6 x 104 cells in 1 mL media per 
well in a 12-well flat bottom plate,  and incubated at 37°C, 5% CO2 for 24 hr. Free 
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BAR or BAR-NPs (1.3 or 3.4 µM) were added to cells in triplicate for 24 hr at 37°C 
in 5% CO2. Fifty microliters of supernatant from free BAR and BAR-NP-treated (1.3 
and 3.4 µM) cells were added to the LDH substrate and incubated at room 
temperature for 30 min. The reactions were subsequently terminated by adding 50 
µL of stop solution. LDH activity was determined by measuring the optical density 
of the solution at 490 nm. Cells treated with staurosporine or with medium only 
served as positive and negative controls for cell death, respectively. 
Apoptosis: The degree to which free BAR or BAR-NPs (1.3 or 3.4 µM) induced 
apoptosis in TIGK cells was determined using the PE Annexin V/Dead Cell 
Apoptosis Kit with SYTOX® Green for Flow cytometry (Invitrogen).  TIGK cells 
were cultured in 12-well microtiter plates with an initial density 2 x 105 cells in 1.5 
ml media.  After 24 hr at 37°C, the medium was decanted, replaced with fresh 
medium containing the desired concentration of BAR or BAR-NPs and incubated 
for an additional 18 hr.  The cells were washed with PBS, trypsinized and 
centrifuged at 250 x g. The cell pellet was suspended in 100 µL of binding buffer 
supplemented with 1 µL Sytox and 5 µL Annexin florescent dye and incubated for 
15 min at 37°C. Samples were then diluted by addition of 400 µL binding buffer 
and analyzed by flow cytometry using a FACScalibur flow cytometer (Becton 
Dickinson), measuring the fluorescence emission at 530 nm and 575 nm.  Cells 
treated with 2 mM hydrogen peroxide or medium only for 4 hr at 37°C and 5% CO2, 





Data from each of the toxicity tests and IL-17 ELISA were analyzed using ANOVA 
after passing Bartlett's and Brown-Forsythe tests for homogeneity of variances 
using GraphPad InStat (La Jolla, CA).  A pair-wise, parametric analysis of variance 
using a Bonferroni multiple comparison post-test was used to determine the 
statistical difference among the individual groups. A P-value of ≤ 0.05 was 
considered to be statistically significant. 
Results 
Nanoparticle Characterization  
The morphology of BAR-NPs, relative to unmodified NPs, is shown in 
Figure 3.1. BAR-NPs demonstrated a spherical morphology without any observed 
changes resulting from conjugation with BAR peptide. The average unhydrated 
diameters of BAR-NPs and unmodified NPs measured from SEM images were 
87.9 ± 29.4 nm and 155.8 ± 37.6 nm, respectively. In comparison, the average 
hydrated diameters of BAR-NPs and unmodified NPs, as measured with dynamic 
light scattering (Malvern Zetasizer) were 333.8 ± 17.8 nm and 312.6 ± 11.2, 
respectively. This is in agreement with previous data demonstrating that BAR-NP 
hydrated diameters were higher than unhydrated diameters 95. The addition of 
positively charge avidin and subsequent conjugation with BAR increased the 
overall charge of BAR-NPs to -10.3 ± 0.9 mV, relative to unmodified PLGA NPs (-




Table 3.1 Physical characterization of NP diameter and surface charge. Data 
represent the mean ± standard deviation of at least 3 independent samples. 








87.9 ± 29.4 333.8 ± 17.8 -10.3 ± 0.9 
Unmodified PLGA NPs 155.87± 37.6 312.6 ± 11.2 -22.6 ± 1.2 
 
 
Figure 3.1 SEM images of (A) BAR-modified PLGA NPs and (B) Unmodified PLGA 
NPs. Scale bar represents 1 µm. Images are representative of a minimum of 3 
independent samples, with n > 500 NPs assessed in total. 
Quantification of BAR Conjugation 
The amount of BAR peptide conjugated to PLGA NPs was determined using 
fluorescence spectroscopy, and the fluorescence was compared to a known 
standard of F-BAR. Previous work in our groups has shown that 3 nmol avidin 
conjugated per mg of PLGA NPs and avidin has four binding sites, with the 
potential to bind 12 nmol of BAR, if all avidin sites were available95,146,150. Loading 
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experiments demonstrated that 7.1 nmol of BAR were bound per mg of PLGA NPs 
(corresponding to 9024 BAR ligands/mg of NP), with a conjugation efficiency 40%. 
Alveolar Bone Loss 
The effectiveness of free BAR and BAR-NPs to inhibit Pg virulence was 
evaluated by measuring Pg-induced alveolar bone loss. Microscopic images of the 
maxilla of sham-infected, Pg/Sg infected, free BAR and BAR-NP-treated mice are 
shown in Figure 3.2.  Quantification of alveolar bone loss showed that mice that 
were infected with both Sg and Pg exhibited significantly (P ≤ 0.0001) increased 
bone loss (-1.37 ± 0.31 mm), relative to uninfected mice or animals infected with 
Sg-only (-0.33 ± 0.07 mm) or Pg-only (-0.44 ± 0.025 mm). Mice that were infected 
with both Sg and Pg and treated with 0.7 or 3.4 µM free BAR exhibited a significant 
reduction in bone loss (-0.69 ± 0.1 mm and -0.56 ± 0.09 mm, respectively), relative 
to infected untreated animals (P ≤ 0.0001).  Mice that were treated with 0.7 µM 
BAR-NP exhibited levels of bone loss (-0.24 ± 0.05 mm) that approached 
uninfected animals. Moreover, 0.7 µM BAR-NP-treated mice showed bone loss 
levels that were significantly lower than bone loss observed in 0.7 or 3.4 µM free 




Figure 3.2 Representative images from different in vivo treatment groups (n=8 per 
group), of the area between the cemento-enamel junction (CEJ) and alveolar bone 
crest (ABC), measured to determine bone loss. Images were taken using a 
dissecting microscope fitted with a video imaging marker measurement system 





Figure 3.3 Alveolar bone loss in each group relative to uninfected, untreated 
control mice. BAR-NP-treated mice showed significant reduction of bone loss 
relative to high and low concentrations of free BAR-treated mice. Data represent 
the mean ± standard deviation (n=8). Statistical differences between groups are 
denoted by **, P ≤0.01; ****, P ≤ 0.0001). 
Histological analysis  
Representative histopathological images of gingival tissues of all mice are 
shown in Figure 3.4. Untreated uninfected gingival tissue shows normal structure 
without inflammatory cell infiltration. However, heavy infiltration of inflammatory 
cells and engorgement of blood vessel are observed in gingival tissue of Pg/Sg 
infected mice as a sign of chronic inflammation, as depicted with black arrows 
(Figure 3.4B). While, gingival tissues of free BAR and BAR-NP-treated mice 
exhibit normal structure with minimal infiltration of inflammatory cells (Figure 3.4C-
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E), suggesting that free BAR and BAR-NPs inhibit biofilm formation and 
consequently periodontitis. Mice treated with 0.7 µM BAR demonstrated higher 
levels of inflammatory cell infiltration relative to control mice; however, still lower 
than that observed in Pg/Sg infected mice. 
 
Figure 3.4 Histological sections of murine periodontal tissues, with inflammatory 
cell infiltration denoted with black arrows. (A) Periodontal tissue of uninfected, 
untreated (control) mice shows normal histological structure without inflammatory 
cell infiltration. (B) Periodontal tissue of Pg/Sg infected mice demonstrates 
prominent chronic inflammation through proliferation of connective tissue and 
heavy infiltration of inflammatory cells. (C) Periodontal tissue of mice treated with 
0.7 µM BAR exhibits medium infiltration of inflammatory cells. (D) & (E) Periodontal 
tissues treated with a higher concentration of free BAR (3.4 µM) or BAR-NPs show 




IL-17 in Periodontal Tissues 
To determine whether free BAR and BAR-NPs reduced gingival 
inflammation, IL-17 levels in gingival tissues were evaluated across all treatment 
groups (see Figures 3.5A and 3.5B). The gingival tissue of Pg/Sg infected mice 
and mice treated with 0.7 µM free BAR demonstrated a statistically significant 
increase in IL-17 gingival tissue fluorescence (~2-fold, P ≤ 0.0001 and ~1.5-fold, 
P ≤ 0.01) relative to uninfected mice.  In contrast, animals treated with 3.4 µM free 
BAR or with BAR-NPs exhibited only a slight increase in IL-17 fluorescence (~1.13-
fold), whereas mice treated with 0.7 µM free BAR showed a ~1.5-fold increase in 
IL-17 fluorescence significantly higher than BAR-NP treated mice (P ≤ 0.05).  





















Figure 3.5 (A) Immunofluorescence staining of IL-17 on gingival tissue 
demonstrated strong staining of the Pg and Sg infected group compared to the 
uninfected, untreated; 0.7 µM BAR; 3.4 µM BAR; and BAR-NP-treated groups.  (B) 
Quantification of IL-17 levels show that free BAR and BAR-NP-treated groups had 
similar IL-17 expression relative to the untreated, uninfected mice; however, mice 
treated with a lower concentration (0.7 µM) of free BAR showed slightly higher, 
statistically significant IL-17 levels relative to untreated, uninfected and BAR-NP-
treated mice. Data represent the mean ± standard deviation (n=5); (*, P ≤ 0.05, ***, 
P ≤ 0.001 ****, P ≤ 0.0001). 
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Determination of BAR and BAR-NP In Vitro Cytotoxicity 
Hemolytic Assay: The cytotoxicity of free BAR and BAR-NPs was initially 
evaluated by measuring the hemolytic activity against 1% sheep red blood cells 
(RBCs). As shown in Figure 3.6A, RBCs that were incubated with free BAR or 
BAR-NPs (1.3 or 3.4 µM), or with PBS (control) showed no hemolysis, suggesting 
that free BAR or BAR-NPs have negligible hemolytic activity in erythrocytes.   
MTT Assay: To assess the effect of free BAR or BAR-NPs on the viability 
of TIGK cells, cultures were incubated with 1.3 or 3.4 µM free BAR for 2 d and 
viability was measured using MTT. As shown in Figure 3.6B, treated cells 
exhibited little loss in viability, suggesting that free BAR and BAR-NPs are 
biocompatible with TIGK cells when applied for up to 2 d.   
ATP Assay: Cytotoxicity was also determined by assessing the metabolic 
activity of TIGK cells by measuring ATP levels. As shown in Figure 3.6C, 
staurosporine-treated cells demonstrated significantly lower levels of ATP (P ≤ 
0.0001) than were observed for uninfected, untreated; free BAR; and BAR-NP-
treated cells. Although the levels of ATP in free BAR and BAR-NP-treated cells 
were statistically different from control cells, their levels were still elevated relative 
to staurosporine-treated cells. 
LDH Assay: Since some peptides are known to damage the cell membrane, 
we next measured LDH activity as a marker for cell membrane integrity after 
treatment with free BAR or BAR-NPs. Figure 3.6D shows that LDH levels released 
from cells treated with free BAR or BAR-NPs (1.3 or 3.4 µM) was negligible when 
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compared to control (medium treated) cells. In contrast, LDH activity released from 
cells treated with staurosporine was significantly (P ≤ 0.0001) higher than control 
or treated cells, suggesting that free BAR and BAR-NPs do not compromise cell 
membrane integrity.  Finally, we examined the ability of free BAR or BAR-NPs to 
induce apoptosis in TIGK cells. Flow cytometry results showed the presence of 
minimal apoptotic populations (lower right quadrant) when cells were incubated 
with 1.3 and 3.4 µM free BAR (3.5 and 14.9%, respectively) or BAR-NPs (12.2 and 
14.2%). In contrast, 89% of cells were apoptotic after treatment with 2 mM 
hydrogen peroxide (Figure 3.7, Table 3.2). These results indicate that free BAR 








Figure 3.6 (A) The hemolytic activity of free BAR or BAR-NPs (1.3, 3.4 µM) was 
assessed after administration to sheep erythrocytes for 3 hr. Hemoglobin release 
from free BAR and BAR-NP-treated cells was negligible relative to release from 
H2O-treated cells (****, P ≤ 0.0001). (B) TIGK cell viability was assessed after free 
BAR or BAR-NPs administration for 2 days. Free BAR and BAR-NPs were non-
toxic, relative to cells treated with DMSO (****, P ≤ 0.0001). (C) ATP levels from 
free BAR (3.4 µM) and BAR-NP-treated (1.3, 3.4 µM) cells showed decreases in 
ATP concentration, relative to control cells (treated with medium only), while ATP 
levels in the staurosporine-treated cells were significantly lower than the control 
(treated with medium only), free BAR, and BAR-NP-treated cells (****, P ≤ 0.0001). 
(D) No significant release of LDH was observed from TIGK cells treated with free 
BAR and BAR-NPs, relative to control cells. Staurosporine-treated cells 
demonstrated significantly elevated LDH levels (****, P ≤ 0.0001). Data represent 




Figure 3.7 TIGK cells were treated with (A) medium alone, (B) 1.3 µM free BAR, 
(C) 3.4 µM free BAR, (D) 1.3 µM BAR-NPs, (E) 3.4 µM BAR-NPs and (F) 2 mM 
hydrogen peroxide. The FITC versus phycoerythrin (PE) fluorescence dot plots 
show the live (bottom left quadrant) and apoptotic cell (bottom right quadrant) cell 






Table 3. 2 TIGK cells apoptosis induced by 1.3 µM free BAR, 3.4 µM free BAR, 
1.3 µM BAR-NPs, 3.4 µM BAR-NPs and 2 mM hydrogen peroxide relative to cells 
treated with medium alone, (*, P ≤ 0.05, **, P ≤ 0.01 and ***, P ≤ 0.001).  
 
Discussion  
Porphyromonas gingivalis adherence to oral streptococci is a key event in 
the initiation and pathogenesis of periodontal diseases, representing a specific 
target for therapeutic intervention105. Previous work in our groups has 
demonstrated that BAR peptide inhibits biofilm formation by preventing Pg 
adherence to streptococci in vitro and in a murine model of infection109,110. 
However, the administration of free BAR was significantly less effective in 
disrupting existing Pg/streptococcal biofilms111-113. A recent study by our groups 
demonstrated the ability of BAR-NPs to deliver a high concentration of peptide to 
potently and multivalently inhibit in vitro biofilm formation95. Given this, the aim of 
this work was to translate our previous in vitro BAR-NP results to a murine model 
Treatment  % Live Cell 
% Early 
Apoptosis 
% Late Apoptosis 
Medium 99.00 ± 1.22 0.80 ± 0.56 0.097 ± 0.06 
BAR 1.3 µM 95.60 ± 1.01 3.39 ± 0.17 0.18 ± 0.09 
BAR 3.4 µM 84.07 ± 0.81* 15.33 ± 0.51* 0.41 ± 0.24 
BAR-NPs 1.3 
µM 
86.57 ± 2.23* 12.53 ± 1.92* 0.22 ± 0.12 
BAR-NPs 3.4 
µM 
83.90 ± 2.55* 14.77 ± 1.53* 0.60 ± 0.44 
2 mM H2O2 12.73 ± 1.59*** 87.03 ± 1.70** 0.23 ± 0.17 
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of periodontitis, highlighting the potential of novel specifically-targeted NPs in a 
prophylactic oral biofilm application. 
Morphological characterization of BAR-modified PLGA NPs showed 
spherical NPs with an average diameter of 87.9 ± 29.4 nm and zeta potential of -
10.3 ± 0.9 mV, while, the diameter and negative surface charge of unmodified NPs 
increased to 155.87± 37.6 nm and -22.6 ± 1.2 mV, respectively. The decrease in 
BAR-NP size may be attributed to the increased surface charge imparted by avidin 
conjugation, which typically reduces aggregation, consequently decreasing NP 
size122,151. The similar, but large increase in size of hydrated NPs, relative to 
unhydrated NPs, may be attributed to PLGA swelling in an aqueous solution115,122. 
These results are in agreement with typically observed NP values95,122. BAR-NPs 
were fabricated using 18 nmol BAR per mg PLGA NP to provide maximum 
conjugation of BAR peptide (7.1 nmol/mg NPs) to the NP surface and the 
functional stability of BAR-NPs relative to free BAR, was tested through in vitro 
biofilm inhibition assays prior to these in vivo experiments.  
To expand upon our in vitro studies, we assessed the efficacy of BAR-NPs, 
relative to free BAR, to prevent alveolar bone loss in a mouse model of 
periodontitis. Mice infected with Pg and Sg showed significantly increased bone 
loss relative to that observed in untreated, uninfected mice, or animals infected 
with Sg or Pg alone.  Treatment with either free BAR or BAR-NPs significantly 
reduced bone loss in Pg/Sg infected mice. Treatment with 0.7 µM or 3.4 µM free 
BAR reduced bone loss in a dose-dependent manner, but interestingly, treatment 
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with 0.7 µM BAR-NPs reduced bone loss to a significantly greater extent than 
either dose of free BAR.  This is consistent with our previous in vitro observations 
that BAR-NPs promote multivalent interactions with Pg95. The reduction of bone 
loss arose from reduced Pg-induced gingival inflammation that most likely 
occurred through BAR-NP-mediated inhibition of Pg colonization of the oral cavity.  
In corroboration with efficacy data, histopathological examination of gingival 
tissues showed minor levels of inflammatory cell infiltration in the gingiva of 
uninfected animals but significantly increased inflammatory cell infiltration in the 
gingiva of Pg/Sg infected mice. Consistent with the bone loss data, treatment with 
free BAR or BAR-NPs significantly reduced inflammation.  In addition, gingival 
tissue levels of the pro-inflammatory cytokine, IL-17, were significantly increased 
upon infection and significantly reduced upon treatment. Finally, free BAR and 
BAR-NPs exhibited minimal toxicity against TIGK cells using various approaches 
to assess cell lysis, induction of apoptosis, or effects of cell viability or metabolism. 
Together, these results indicate the utility of BAR-NPs to provide and enhance 
protection in a murine model of periodontitis, relative to treatment with free BAR.  
To date, a variety of groups have developed polymeric delivery vehicles to 
improve traditional treatment and prevention approaches to periodontal 
diseases86. However, polymeric delivery vehicles have been primarily developed 
to deliver antibiotics85,86,90,152,153 for prolonged durations, and to decrease antibiotic 
dose, administration frequency, and associated adverse effects. However, 
antibacterial resistance and non-specificity still remain challenges to effectively 
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eradicate initial and recurrent biofilms, pathogen resistance, and associated 
diseases35,37,107 . While recent studies have demonstrated some success using 
various polymeric NPs in dental pathogen murine models85,86, these studies have 
focused on targeting antibiotic NP formulations to epithelial cells with gingival 
targeting RGD peptides. Results from these studies indicated that NP surface-
modification improved NP attachment to epithelial cells, maintaining antibacterial 
(i.e., minocycline) concentrations in gingival fluid for prolonged durations and 
improved therapeutic activity relative to unmodified NPs94. Other studies have 
similarly sought to use RGD94, or more general bioadhesive molecules such as 
chitosan124,126 or dimethyl-octyl ammonium134, to obtain improved localization and 
adhesion to the dental surface. Strong mucoadhesive properties and adhesion to 
the tooth surface were demonstrated for antibacterial NPs modified with these 
agents124.   
Although non-specific mucoadhesive molecules and broad targeting 
molecules such as RGD have demonstrated promise in establishing adhesion, the 
challenges surrounding antibiotic active agents have spurred the discovery and 
investigation of specifically-targeted molecules against oral biofilms. Antimicrobial 
peptide (HHC-36) loaded titanium oxide nanotubes, titanium binding peptide 
(TiBP-1), histatin 5, and lactoferricin peptides have been developed to enhance 
pre-implant protection against bacterial infection and prevent biofilm formation154-
156. In addition, a terminal product of the cyclooxygenase (COX)-2 pathway (15d-
PGJ2) has been administered to inhibit bone resorption in vivo133. PLGA NPs, 
encapsulating 15d-PGJ2, localized in gingival tissue, showed potent anti-
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inflammatory response by decreasing proinflammatory cytokines, demonstrated 
immunomodulatory effects, and decreased bone resorption in a mouse model of 
periodontitis after daily s.c. injection133. 
 In contrast with the non-specific bioadhesive and targeting developments 
described above, the goal of this work was to incorporate a pathogen-specific 
biological active agent within a surface modification, to exploit the specific and 
adhesive interactions between two bacteria known to initiate the process of 
periodontal infections. Previous in vitro studies conducted by our group have 
demonstrated that BAR-modified NPs exhibit potent biofilm inhibition with a 7-fold 
lower IC50, relative to free BAR95, highlighting the benefits of a multivalent delivery 
system to enhance binding to target sites. Seminal work in the area of multivalency 
demonstrated that multivalent ligands can enhance the strength or binding avidity 
to target sites, relative to that observed with monovalent ligands, by increasing the 
affinity to target entities while decreasing detachment rates121,145,157. Our prior in 
vitro results with BAR-NPs are consistent with the enhanced binding anticipated 
via these mechanisms, demonstrating improved effectiveness, with lower BAR 
concentration. Importantly, results from our current in vivo studies corroborate the 
in vitro multivalent effects, by demonstrating that 0.7 µM BAR, conjugated to a NP 
surface, safely and significantly reduces bone loss and inflammation, relative to a 
higher concentration of monovalent free BAR (3.4 µM), in a murine model of 
infection. Moreover, BAR-NPs, within the range of concentrations examined in this 
study, provide a safe method, as assessed with four different studies, to induce 
biofilm inhibition. The use of biodegradable FDA-approved polymers, such as 
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PLGA, as a core platform, offers the potential for the incorporation of other 
complementary active agents, and more seamless integration in pre-clinical and 
clinical studies. Ongoing studies in our group will utilize these particles in dual 
capacity to both multivalently target specific species of bacteria and to release 
active agents simultaneously. 
In future studies, we intend to examine different temporal administration 
regimens to optimize prevention and treatment approaches with this platform. In 
addition, we plan to extend our studies to assess the kinetics of BAR-NPs in the 
oral cavity after gingival application, and correlate this with BAR-NP effectiveness 
in preventing (or treating) biofilm formation. Moreover, we will evaluate the stability 
and longevity of BAR-NP binding with Pg in the oral cavity. Long-term, clinical 
studies will focus on formulating BAR-NPs to more conveniently apply BAR-NPs 
to the oral cavity, for example, in a mouthwash or gel, with the goal of retaining 
BAR-NPs in oral niches for durations spanning 12-24 hr. While existing products 
designed for localized periodontal prevention and treatment contain antibiotics, 
analgesic, or anesthetic cargos, we envision that this technology may offer a new 
way to deliver specifically- acting biologics to the oral cavity.  
Conclusions 
Building upon our previous in vitro work, the goal of these studies was to 
assess the in vivo efficacy and safety of BAR-NPs in a murine model of 
periodontitis. We hypothesized that BAR-NPs may more potently and safely inhibit 
Pg virulence in vivo by delivering a high localized concentration of BAR, and 
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improving BAR effectiveness through multivalent interactions with Pg. The in vivo 
efficacy of BAR-NPs was evaluated in a periodontitis murine model by measuring 
bone loss, histologic changes, and gingival IL-17 expression as outcomes of Pg-
induced inflammation. The safety of BAR-NPs was evaluated by measuring cell 
viability, apoptosis, ATP and LDH levels in TIGK cells and hemolytic activity in 
sheep erythrocytes. BAR-NPs significantly reduced bone loss and IL-17 
expression in Pg/Sg infected mice to levels of sham-infected mice, and to a greater 
extent than an equimolar amount of free BAR. Moreover, BAR-NPs and free BAR 
showed non-hemolytic activity and demonstrated greater than 90% viability, with 
apoptosis, ATP and LDH levels similar to untreated cells. Our results suggest that 
BAR-NPs provide a potent platform to inhibit Pg virulence, relative to free BAR, 
while eliciting a safe, non-toxic effect within the evaluated concentration range of 
1.3 - 3.4 µM on gingival and erythrocytic cells, suggesting this novel therapeutic 




RAPID-RELEASE POLYMERIC FIBERS FOR INHIBITION OF 
PORPHYROMONAS GINGIVALIS AND STREPTOCOCCUS GORDONII 
BIOFILMS 
Introduction   
Various mechanical prophylactic therapies including scaling and root 
planning are only temporarily effective in removing the subgingival biofilm to halt 
the inflammatory cascade29, since the biofilm begins to re-form shortly after 
prophylaxis is completed. Furthermore, while current medicinal therapies, 
consisting of systemic and local administration of antibiotics are initially effective, 
they can result in side effects due to an inadequate concentration of drug reaching 
the periodontal pockets resulting in transient activity35,37,107, and lead to the 
development of antimicrobial resistance. Moreover, the non-specific nature of 
current antibiotic agents can adversely impact the commensal microbial 
community. Given these challenges, new prophylactic and therapeutic approaches 
that provide more specific targeting of periodontal pathogen interactions are 





Delivery vehicles that localize the delivery and maintain the stability of 
specifically-targeted biologics, such as BAR peptide, may offer improved functional 
activity, thereby enhancing the therapeutic efficacy28.  Delivery platforms such as 
electrospun fibers (EFs) have been used in a variety of applications like wound 
dressing158, tissue regeneration159,160 and antimicrobial delivery98,97 to incorporate 
water-soluble bioactive agents such as proteins, peptides, nucleic acids and 
hydrophilic/hydrophobic drugs. Polymeric fibers can protect encapsulated cargo 
from systemic absorption and associated side effects. Moreover, electrospinning 
offers a cost-effective, reproducible, and highly tunable method to provide efficient 
encapsulation and release based on the needs of rapid-onset or prolonged delivery 
applications. Many studies have shown that fibers composed of polymer blends 
have the potential to tune drug miscibility and that the resulting drug-polymer 
interactions may lead to different release profiles99. A number of natural, synthetic 
and semi-synthetic polymers have been used. Since biocompatible, 
biodegradable, and Food and Drug Administration (FDA) approved polymers 
including poly(lactic-co-glycolic) acid (PLGA)102, poly(L-lactic acid) (PLLA)103, 
polycaprolactone (PCL)97, and polyethylene oxide (PEO)104 have been 
successfully electrospun into fibers, using this approach, we hypothesized that EFs 
may offer advantages to the administration of BAR peptide in the oral cavity.  
We previously showed that BAR-modified and BAR-encapsulated 
nanoparticles (NPs) inhibit Pg biofilm formation95,96,143. These NPs were 
envisioned to serve in formulations such as an oral gel, varnish or mouthwash that 
require two to three daily applications. Here we sought to develop and characterize 
78 
 
EFs that may be administered in future applications, as rapid-release dental strips 
in the oral cavity. We hypothesized that BAR release may be modulated by 
changing the hydrophobic:hydrophilic polymer ratios of the blended fibers. We 
synthesized blended EF formulations and showed that changing the 
hydrophobic:hydrophilic polymer ratios altered the release kinetics of BAR peptide 
and functionally characterized their effectiveness in preventing the formation of 
Pg/Sg biofilms in vitro. These results suggest that BAR-incorporated EFs can be 
formulated to release peptide over a time window of hours and may represent a 
new dosage form that can release targeting molecules in the oral cavity. Long-
term, we envision that BAR-EFs may provide a promising rapid-release platform 
to deliver BAR peptide to the oral cavity in the form of strips or gum that can be 
applied twice daily to inhibit biofilm formation.  
Materials and Methods   
Materials 
 Hydrophobic polymers including poly(lactic-co-glycolic acid) (PLGA, 50:50 
lactic:glycolic acid, MW 30,000-60,000), poly(L-lactic acid) (PLLA, MW 50,000), 
and polycaprolactone (PCL, MW 80,000), and the hydrophilic polymer, 
polyethylene oxide (PEO, MW 100,000) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Tris-EDTA (TE) buffer (pH 8.0), phosphate buffered saline (PBS) 
and the organic solvents chloroform, dimethyl sulfoxide (DMSO), and 
hexafluoroisopropanol (HFIP) were also purchased from Sigma-Aldrich (St. Louis, 
MO, USA). All chemicals were used directly without further purification. One 
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milliliter plastic syringes, petri dishes, and 20 mL scintillation vials were obtained 
from VWR. One milliliter glass syringes were purchased from Fisher Scientific. The 
electrospinner was provided courtesy of Dr. Stuart Williams at the Cardiovascular 
Innovative Institute, University of Louisville. 
Peptide Synthesis 
 The peptide used in this study (NH2-
LEAAPKKVQDLLKKANITVKGAFQLFS-COOH)112 was synthesized by 
BioSynthesis, Inc. (Lewisville, TX). It was obtained with purity greater than 90% 
and comprised residues 1167 to 1193 of the SspB (Antigen I/II) protein sequence 
of Sg. A fluorescent BAR peptide (F-BAR), synthesized by covalently attaching 6-
carboxyfluorescein (F-BAR) to the epsilon amine of the lysine residue underlined 
in the sequence above, was used to more easily characterize BAR loading and 
release from the fibers via fluorescence detection. 
Preparation of Polymer Solutions 
To prepare the hydrophobic-only polymer fiber batches, PLGA and PLLA 
were dissolved in HFIP at a concentration of 15% (w/w), while PCL was dissolved 
in HFIP at a concentration of 12% w/w due to increased viscosity. The polymer 
solutions were aspirated into a 7 mL glass scintillation vials, and sealed using 
parafilm to prevent evaporation of the organic solvent. The vials were placed in a 
shaker at 150 rpm and incubated at 37°C overnight to solubilize the polymer. The 
final volume of each polymer solution was 1 mL. The following day, F-BAR peptide 
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was dissolved in 200 µL TE buffer. The F-BAR solutions were mixed with the 
polymer solvents at a concentration of 1% w/w (e.g., 2.4 mg BAR/240 mg polymer). 
To prepare blended polymers, the hydrophobic polymers PLGA, PLLA, and PCL 
were mixed with PEO at different ratios (40:60, 20:80, 10:90 w/w) to form 
PLGA:PEO, PLLA:PEO, and PCL:PEO blends in chloroform at a concentration of 
15% (w/v). The blended solutions were aspirated into 20 mL glass scintillation 
vials, and sealed using parafilm to prevent evaporation of the organic solvent. The 
vials were placed in a shaker at 150 rpm and incubated at 37°C overnight to 
solubilize the polymer. The final volume of each polymer solution was 1 mL. The 
following day, F-BAR peptide was dissolved in 60 µL DMSO. The F-BAR solutions 
were mixed with the polymer solvent at a concentration of 1% w/w (BAR/polymer 
content). 
Electrospinning  
For the non-blended polymer solutions, 1 mL of the mixed polymer 
suspension was aspirated into a 1 mL plastic syringe with an 18-gauge blunt 
needle tip. The internal diameter of the BD plastic syringe (4.78 mm), was set in 
the syringe pump program. The collector was adjusted such that there was at least 
10 cm distance maintained from the needle tip. The syringe pump motor controls 
were adjusted by setting the “slide” control to 4.5 and the “rotor” to 8.  The voltage 
supply was set at 20 kV, and the syringe pump flow rate was set to 0.8 mL per 
hour. The polymer solution was electrospun at room temperature, under 
atmospheric conditions, for 1 hr 15 min, and the resulting fine mist was collected 
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on the mandrel and allowed to dry for 15 min (Figure 4.1). The mandrel was 
removed from the collector and the fiber was cut and gently peeled off the mandrel. 
The fiber was placed in a labeled petri dish and kept in a desiccator for 24 hr before 
characterization. The desiccated fibers were stored in 4°C until use. 
For the blended polymer solutions, 1 mL of the mixed dual-polymer 
suspension was aspirated into a 1 mL glass syringe with a 22-gauge blunt needle 
tip. The internal diameter of the Hamilton gastight syringe (4.61 mm), was set in 
the syringe pump program. A distance of 15 cm was kept between the needle tip 
and the collector. The “slide” control was set to 4.5 and the “rotor” control was set 
to 8.  A voltage of 20-25 kV was applied, at a flow rate of 0.3 mL per hr. The 
electrospinning processes were employed under ambient conditions for 3 hr 20 
min. The stretched and solidified polymeric fibers were collected on a 4 mm 
diameter stainless steel mandrel and allowed to dry for 15 min. Similar desiccation 




Figure 4.1 Schematic representation of electrospinning process. Adapted from 
http://www.people.vcu.edu/~glbowlin/research.html. 
EF Characterization: EF Morphology, Diameter, BAR Loading, and Release 
 Fiber morphology and size were evaluated using scanning electron 
microscopy (SEM) (JSM-820, JEOL, Tokyo, Japan), and fiber diameters were 
obtained by analyzing SEM images with NIH ImageJ. The loading and 
encapsulation efficiency (EE) of F-BAR peptide in the non-blended and blended 
fibers were determined by dissolving F-BAR fibers in DMSO. The fiber solution 
was subsequently vortexed, sonicated for 5 min, and dissolved for 1 hr in a dark 
room. The quantity of extracted F-BAR was determined by measuring the 
fluorescence using a spectrophotometer (488/518 nm excitation/emission), 
relative to an F-BAR standard. A standard curve of F-BAR was obtained by adding 
0.1 mg F-BAR to 1 mL of 1:9 DMSO:TE, and serially diluting in 1:9 DMSO:TE. The 
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diluted solutions (100 µL/well) were transferred to a 96-well clear bottom microtiter 
plate in triplicate. For the dissolved fiber samples, after the incubation period, the 
fiber sample solutions were vortexed and sonicated again. The solutions were 
diluted 1:2, 1:5, 1:10 and 1:100 in 1:9 DMSO:TE solution, and transferred to a 
microtiter plate. 
 The in vitro release of F-BAR from fibers was measured by gentle agitation 
of EFs in phosphate buffered saline (PBS, pH 7.4) at 37°C. At fixed time points (1, 
2, 4, 8, 12, and 24 hr), samples were collected and the amount of F-BAR released 
from the EFs was quantified via fluorescence spectroscopy, against an F-BAR 
standard in PBS.  
Growth of Bacterial Strains 
 Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories 
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL 
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under 
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently 
inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aero-
bically without shaking in brain-heart infusion broth (Difco Laboratories Inc.) 
supplemented with 1% yeast extract for 16 hr at 37°C. 
Biofilm Inhibition Assay  
 To assess the effectiveness of BAR-incorporated EFs to prevent the 
interaction of Pg with Sg, Sg was harvested from culture and labeled with 20 µL of 
84 
 
5 mg/mL hexidium iodide for 15 min at room temperature. Following incubation, 
cells were centrifuged to remove unbound fluorescent dye. The bacterial 
concentration was subsequently measured by the O.D. (600 nm) from twenty-fold 
diluted cultures of Sg. The optical density of Sg cells was adjusted to 0.8 O.D. 
(1 × 109 CFU/mL) to obtain uniformity between cell counts in each well. After 
adjusting the optical density, 1 mL of Sg cells was added to each well of 12-well 
culture plates containing a sterilized micro-coverslip. The cell culture plates were 
wrapped in aluminum foil to protect the labeled cells from light and placed on a 
rocker platform in the anaerobic chamber for 24 hr. Pg cultures were optimized 
using a similar approach, utilizing a different fluorescent label (20 µL of 4 mg/mL 
carboxyfluorescein–succinylester). Pg was incubated with the fluorescent dye for 
30 min on a rocker platform and protected from light. The same procedures were 
followed as performed with Sg to determine cell concentration, with slight 
adaptations. The optical density of Pg was adjusted from 0.8 to 0.4 O.D. 
(5 × 107 CFU/mL) by diluting Pg cultures with an equal volume of 1X PBS 
containing BAR-EFs, free BAR, or blank EFs as a control, to a final volume 1 mL. 
The final concentration of BAR- EFs or free BAR ranged from 0.3-3 µM based on 
the previously determined IC50 of free BAR (1.3 µM). Pg was incubated with BAR-
EFs, free BAR, or blank EFs at 25°C for 30 min before transferring to wells 
containing Sg. 
 Plates containing Pg and Sg were subsequently incubated for 24 hr at 37°C 
in anaerobic conditions. The following day, the supernatant was removed and cells 
were washed with PBS. Adherent cells were fixed with 4% (w/v) paraformaldehyde 
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and the cover glass was mounted on a glass slide. Biofilms were visualized using 
a Leica SP8 confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL) 
under 60x magnification. Background noise was minimized using software 
provided with the Leica SP8 and three-dimensional z-stack biofilm images were 
obtained from 30 randomly chosen frames using a z-step size of 0.7 μm. Images 
were analyzed with Volocity image analysis software (version 6.3; Perkin Elmer, 
Waltham, MA, USA) to determine the ratio of green to red fluorescence (GR), 
representing Pg and Sg, respectively. Control samples were used to subtract 
background levels of auto-fluorescence. Briefly, triplicate samples of Sg alone 
were immobilized without Pg or BAR in 12-well culture plates and the same 
procedures for dual-species biofilm were followed. Sg-only coverslips were 
visualized and images were analyzed as described above. The GR background 
was subtracted using the following formula: GR sample or control - GR Sg-only. 
Each treatment group (BAR-EFs or free BAR) was analyzed in triplicate and three 
independent frames were measured for each well. GraphPad InStat (La Jolla, CA) 
was used for data analysis and differences were considered to be statistically 
significant when P ≤ 0.05. The percent inhibition of Pg adherence was calculated 
with the following formula: GR sample/GR control.  
Biofilm Disruption Assay 
 The same procedures utilized in the inhibition assay were followed, except 
Pg was allowed to adhere to streptococci in the absence of BAR peptide or BAR-
EFs to demonstrate the ability of BAR-incorporated EFs to disrupt or “treat” pre-
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established biofilms. The resulting Pg/Sg biofilms were then treated for the 
maximum duration observed for free BAR to disrupt existing biofilms (3 hr)95. 
Established biofilms were administered BAR-EFs, free BAR or blank EFs at 
various concentrations in 1mL PBS, and processed and analyzed as described 
above. The mean and standard deviation (SD) between samples were determined 
and the percent disruption of Pg adherence was calculated with the following 
formula: GR sample/GR control.  
Tissue Culture 
 Telomerase immortalized gingival keratinocytes (TIGKs) were grown on 12-
well collagen-coated plates (Becton Dickinson, Bedford, MA) and cultured using 
DermaLife K Calcium Free Medium (LifeFactors®) supplemented with 
penicillin/streptomycin (100 U/mL final concentration; St. Louis, MO), insulin (5 
µg/mL), recombinant human (rh), L-glutamine (6 mM), apo-transferrin (5 µg/mL), 
epinephrine (1 µM), rh TGF-α (0.5 ng/ mL), extract PTM, calcium chloride (0.06 mM) 
and hydrocortisone hemisuccinate (100 ng/mL). The cells were incubated at 37°C 
in the presence of 5% CO2 for 6 days until they reached 95% confluence. 
Determination of BAR and BAR-EFs In Vitro Toxicity 
Hemolytic Assay: A sample of 250 µL of 1% sheep erythrocytes (Rockland 
Inc, Pennsylvania, USA) was suspended in sterile PBS. 1.3 and 3.4 µM (the 
maximum concentrations used in in vitro and in vivo studies) of BAR peptide or 
10:90 PLGA:PEO BAR-EFs were added to sheep erythrocytes. Water replaced 
PBS as a positive control for cell hemolysis. The suspension was incubated at 
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37°C for 3 hr then centrifuged at 3,500 x g, Hemoglobin released due to cell lysis 
was analyzed by measuring the absorbance at 541 nm. 
MTT Assay: TIGK cells were seeded in 12-well plates at a density of 6 x 104 
cells in 1 mL media per well and incubated for 24 hr to allow for 60–70% confluency 
and sufficient adhesion. Cells were treated with 1.3 or 3.4 µM of BAR or BAR-EFs. 
After 24 hr, 100 µL of MTT solution was added to the media of all samples. After 4 
hr incubation at 37°C, 550 µL of lysis buffer was added to the media of each well 
and plates were incubated for overnight. The absorbance of each well was read at 
570 nm, and the sample absorbance was normalized to the absorbance of 
medium-only treated cells. Cells were treated with 10% DMSO media (100 µL 
DMSO in 900 µL media) as a positive control for cell death. 
ATP Assay: The metabolic activity of cells was assessed by measuring total 
ATP levels using the CellTiter-Glo reagent (Promega, Madison WI), as described 
by the manufacturer. TIGK cells were seeded at a density of 6 x 104 cells in 1 mL 
media per well and incubated at 37°C, 5% CO2 for 24 hr in a 12-well flat bottom 
plate.  Cells were then incubated with BAR or BAR-EFs (1.3 or 3.4 µM) for 24 hr 
at 37°C in 5% CO2. Cells were then lysed with 500 µL of 0.1% Triton X-100 for 30 
min at 37°C. The lysates were collected and centrifuged at 1,000 x g for 10 min at 
4°C, and 50 µL of supernatant was mixed with 50 µL of CellTiter-Glo reagent. 
Samples were incubated at ambient temperature for 10 min in a black 96-well plate 
in the dark. Total luminescence was measured with a Victor 3 luminometer (Perkin-
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Elmer, Inc). Cells incubated with 1 ng of staurosporine or with medium-only served 
as positive and negative controls for cell death, respectively. 
LDH Assay: Cell membrane leakage was measured by assessing the 
release of lactate dehydrogenase (LDH).  Extracellular LDH was quantified using 
a CytoTox96® non-radioactive cytotoxicity assay (Promega, Madison WI) as 
described by the manufacturer. TIGK cells were plated at density of 6 x 104 cells 
in 1 mL media per well in a 12-well flat bottom plate, and incubated at 37°C, 5% 
CO2 for 24 hr. BAR or BAR-EFs (1.3 or 3.4 µM) were added to cells in triplicate for 
24 hr at 37°C in 5% CO2. Fifty microliters of supernatant from free BAR and BAR- 
EFs-treated (1.3 and 3.4 M) cells were added to the LDH substrate and incubated 
at room temperature for 30 min. Then the reactions were terminated by adding 50 
L of stop solution. LDH activity was determined by measuring the optical density 
of the solution at 490 nm. Positive control cells were treated by Staurosporine, 
while negative control cells treated with medium only.  
Oxidative DNA Damage: Free radicals and other reactive species are 
generated from cells under stress and cause oxidative damage to biomolecules. 
DNA is the most targeted site of oxidative attack. Apurinic/apyrimidine (AP or 
abasic) site is a prevalent oxidative DNA damage lesion. OxiSelect™ Oxidative 
DNA Damage Quantitation Kit (Cell Biolabs, INC., San Diego, CA, USA) was used 
to quantify AP sites in cells treated with free BAR or BAR-EFs (1.3 or 3.4 µM) as 
described by the manufacturer. TIGK cells were plated at density of 6 x 104 cells 
in 1 mL media per well in a 12-well flat bottom plate, and incubated at 37°C, 5% 
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CO2 for 24 hr. BAR or BAR- EFs (1.3 or 3.4 µM) were added to cells in triplicate 
for 24 hr at 37°C in 5% CO2. Cells treated with medium-only and 2mM H2O2 served 
as negative and positive controls, respectively. Genomic DNA was isolated from 
TIGK cells by QIAamp DNA Mini kit (Qiagen). AP sites were determined in genomic 
DNA by using biotinylated aldehyde reactive probe (ARP) that reacts specifically 
with an aldehyde group of AP sites, then were colorimetric detected by a 
streptavidin–enzyme conjugate at 450 nm. The quantity of AP sites in DNA 
samples was determined by comparing the absorbance with standard curve of 
known amount of AP sites.    
Statistical Analysis 
 Data from each of toxicity tests were analyzed using ANOVA after passing 
Bartlett's and Brown-Forsythe tests for homogeneity of variances using GraphPad 
InStat (La Jolla, CA). A pair-wise, parametric analysis of variance using a 
Bonferroni multiple comparison post hoc test was used to determine the statistical 
difference among the individual groups. A P-value of ≤ 0.05 was considered to be 
statistically significant. 
Results 
EF Characterization: EF Morphology, Diameter, BAR Loading, and Release 
Fibers morphologies and diameters are shown in Figures 4.2 and 4.3.  The 
average diameters of EFs ranged from 0.7 to 1.3 μm with no statistically significant 
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differences observed within or across different formulations, as a function of 
polymer type or blend ratio. 
 
 
Figure 4.2 (A) SEM images of 1% w/w BAR PLGA, PLLA, and PCL non-blended 
fibers. (B) SEM images of 40:60, 20:80, and 10:90 1% w/w BAR blended 




Figure 4.3 Average diameters of electrospun fibers measured from SEM images, 
using ImageJ. (A) Non-blended and blended (B) 40:60, (C) 20:80, and (D) 10:90 
PLGA:PEO, PLLA:PEO and PCL:PEO 1% w/w BAR fibers. Error bars represent 
the mean ± the standard deviation (n=3) of three independent runs. 
BAR Loading and Release 
The overall polymer yield after electrospinning ranged from 40-60% for the 
non-blended fiber formulations, while the blended fibers achieved higher yields 
spanning 80-90%. The total F-BAR loading for non-blended and blended EFs 
ranged between 4.6 – 6.9 µg BAR/mg polymer and 6.0 – 9.2 µg BAR/mg polymer, 
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respectively, indicating that high loading of F-BAR was achieved in all fiber 
formulations (Table 4.1). To determine the amount of F-BAR release from the 
different fiber formulations, F-BAR EFs were incubated in PBS at 37°C. The 
fluorescence of the collected supernatant was measured at 1, 2, 4, 8, 12 and 24 
hr. Figure 4.4 shows the cumulative release of F-BAR from non-blended EFs at 
each time point over a 24 hr duration. PLGA EFs demonstrated minimal release of 
F-BAR (9.5% of total loading) after 24 hr, while PLLA and PCL fibers showed even 
less release during the same duration. Overall, EFs consisting of only hydrophobic 
polymers (i.e., non-blended formulations) demonstrated minimal release relative 
to the PEO-blended EFs.  
Figure 4.5 shows the release of F-BAR from blended PLGA:PEO, 
PLLA:PEO and PCL:PEO fibers with different blend ratios (40:60, 80:20, 90:10), 
as a function of hydrophobic polymer type. The importance of the PEO ratio in 
each hydrophobic fiber type, is shown in Figure 4.5, with the 10:90 formulation 
providing maximum release of F-BAR for each hydrophobic blend. Fibers 
comprised of 10:90 PLGA:PEO released 8.25 µg/mg, corresponding to 93% of the 
incorporated F-BAR within the first 2 hr, relative to PLLA:PEO and PCL:PEO 10:90 
fibers with 65% and 45% of F-BAR release, respectively (Figure 4.6). A significant 
reduction in the release of F-BAR was observed after 2 hr for all 10:90 
formulations. For the 20:80 blended formulations, the PLGA:PEO fibers showed 
maximum release of 88%, compared to PLLA:PEO and PCL:PEO at 58% and 
25%, respectively, after 2 hr. Similar trends in F-BAR release were observed for 
the 40:60 formulations with PLGA:PEO exhibiting the maximum release of 78%, 
93 
 
and PLLA:PEO  and PCL:PEO releasing 45% and 17% after 2 hr. Of the tested 
formulations 40:60 PLGA:PEO, PLLA:PEO and PCL:PEO released the least F-
BAR within the first 2 hr, and a significant reduction in release was observed after 
~4 hr for both the 20:80 and 40:60 formulations. Overall, the release trends for the 
different ratios of polymer blends were similar, with PLGA blends achieving the 















Table 4.1 The amount of BAR loaded in non-blended and blended polymeric EF 
formulations (µg/mg) and percent of total BAR loaded in blended and blended EFs. 
High loading capacity and encapsulation efficiency was achieved with all fiber 
formulations. However, non-blended EFs showed comparatively lower polymer 
yield and encapsulation efficiency, relative to the blended EFs. Data represent the 

















59.0 6.9 ± 0.1 69 ± 2.5 
PCL 51.0 6.0 ± 0.4 60 ± 4.0 
PLLA 42.3 4.6 ± 0.6 46 ± 5.2 
PLGA:PEO 
40:60 
82.9 7.4 ± 0.5 74 ± 5.5 
PCL:PEO 91.5 8.6 ± 0.2 86 ± 2.4 
PLLA:PEO 82.0 9.1 ± 0.3 92 ± 3.1 
PLGA:PEO 
20:80 
80.9 8.8 ± 0.2 88 ± 2.6 
PCL:PEO 89.3 8.9 ± 0.4 89 ± 4.0 
PLLA:PEO 85.2 8.3 ± 0.4 83 ± 4.2 
PLGA:PEO 
10:90 
82.8 8.8 ± 0.5 88 ± 5.6 
PCL:PEO 80.0 6.0 ± 0.4 60 ± 4.0 




Figure 4.4 The cumulative release of F-BAR from 1% w/w F-BAR non-blended 
(100:0) PLGA, PLLA and PCL fibers. The cumulative release is reported as (A) µg 
F-BAR per mg of fiber, and (B) percent of total loaded F-BAR. PLGA showed the 
greatest release of incorporated BAR among the non-blended formulations at 24 












Figure 4.5 The cumulative release of F-BAR from 1% w/w F-BAR blended 
PLGA:PEO, PLLA:PEO and PCL:PEO fibers (A) 40:60, (B) 20:80, and (C) 10:90. 
The cumulative release is reported as the total quantity of F-BAR released on the 
left (µg F-BAR per mg of fiber), and as the percent of total loaded F-BAR on the 





Figure 4.6 The cumulative release of F-BAR from the non-blended and PEO-
blended formulations as a function of hydrophobic polymer type (A) PLGA, (B) 
PLLA, or (C) PCL and PEO ratio in each blend. The release of encapsulated BAR 
increases with an increase in PEO fraction. PLGA and PEO blends exhibit the most 
significant and rapid F-BAR release, relative to PLLA and PCL blends.  For all 
polymer types, the 10:90 blends show the greatest release of BAR as compared 
to the 20:80 and 40:60 formulations at any given time point. PLGA:PEO (10:90) 
fibers provide the highest amount of BAR release across formulations. Data 
represent the mean ± standard deviation (n=3) of three independent runs. 
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Pg/Sg Biofilm Inhibition  
Given that the PLGA blends achieved the highest release of F-BAR, the 
ability of the 10:90 PLGA:PEO BAR-EFs to inhibit or “prevent” Pg biofilm formation 
was assessed, relative to the administration of free BAR. To assess inhibition, 
10:90 PLGA:PEO BAR-EFs or free BAR were administered to Pg for 24 hr. 
Subsequently, BAR-EF or free BAR-treated Pg was incubated with immobilized 
Sg.  As shown in Figures 4.7 and 4.9A, Pg adherence was significantly reduced 
in the presence of 10:90 PLGA:PEO BAR-EFs. Biofilm formation was inhibited by 
31, 42, or 82% by 0.3, 0.7, and 3.0 µM BAR-EFs. The maximum inhibition 
observed was similar to the 81% inhibition observed with free BAR (3 µM). BAR-
incorporated EFs potently inhibited biofilm formation in a dose-dependent manner 
(IC50 = 1.3 µM); however, no statistically significant differences (P > 0.05) in 
inhibition between BAR-incorporated EFs and free BAR were observed. 
Pg/Sg Biofilm Disruption  
The ability of the 10:90 PLGA:PEO BAR-incorporated EFs to disrupt or 
“treat” pre-existing Pg/Sg biofilms was assessed (Figures 4.8 and 4.9B). Dual-
species biofilms were formed for 24 hr, and were subsequently incubated for 3 hr 
with BAR-incorporated EFs or free BAR. Biofilm formation was disrupted by 29, 
34, or 66% by 0.3, 0.7, and 3.0 µM BAR-EFs. The maximum inhibition observed 
was similar to the 66% inhibition observed with free BAR (3 µM). Taken together, 
BAR-EFs exhibited efficient biofilm disruption (IC50 = 2 µM) that was similar to free 




Figure 4.7 BAR-incorporated PLGA:PEO (10:90) EFs prevent Pg adherence to 
Sg. Biofilms were visualized with confocal microscopy and the ratio of green (Pg) 
to red (Sg) fluorescence in z-stack images was determined using Volocity image 






Figure 4.8 BAR-incorporated PLGA:PEO (10:90) EFs disrupt pre-established Pg-
Sg biofilms. Biofilms were visualized with confocal microscopy and the ratio of 
green (Pg) to red (Sg) fluorescence in z-stack images was determined using 










Figure 4.9 (A) Biofilm inhibition and (B) biofilm disruption, as a function of different 
concentrations of BAR-incorporated PLGA:PEO (10:90) EFs and free BAR (3 µM). 
Data represent the mean ± standard deviation (n=6). 
Assessment of BAR and BAR-EFs In Vitro Cytotoxicity 
Hemolytic Assay: The cytotoxicity of free BAR and 10:90 PLGA:PEO BAR-
EFs was initially assessed by measuring the hemolytic activity against sheep red 
blood cells (RBCs). As shown in Figure 4.10A, neither free BAR nor BAR-EFs (1.3 
or 3.4 µM) induced hemolysis of RBCs.   
MTT Assay: To determine the effect of free BAR or BAR-EFs on TIGK cell 
viability, cells were treated with free BAR or BAR-EFs (1.3 or 3.4 µM) and viability 
was assessed using the MTT assay. As shown in Figure 4.10B, free BAR (1.3 or 
3.4 µM) treated cells exhibited little non-significant loss in viability while BAR-EF 
(1.3 or 3.4 µM) treated cells showed higher viability, relative to medium-only 
treated cells.   
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ATP Assay: The metabolic activity of TIGK cells was assessed by 
measuring ATP levels. As shown in Figure 4.10C, cells treated with free BAR (1.3 
or 3.4 µM) and BAR-EFs (1.3 µM) showed negligible decreases in ATP relative to 
medium-only treated cells, while, cells treated with BAR-EFs (3.4 µM) exhibited 
slightly lower levels of ATP relative to medium-only treated cells (P ≤ 0.01). 
Staurosporine-treated cells demonstrated significantly lower levels of ATP (P ≤ 
0.0001) than were observed for medium-only, free BAR, and BAR-EF treated cells. 
LDH Assay: Since some peptides are known to damage the cell membrane, 
LDH released in the cell media was evaluated as a marker for cell membrane 
integrity after free BAR or BAR-EF treatment. Figure 4.10D shows that free BAR 
or BAR-EFs (1.3 or 3.4 µM) induced a little non-significant increase in release of 
LDH from cells, relative to LDH levels released from medium-only treated cells. 
However, staurosporine induced a significantly higher level of LDH released from 
TIGK cells relative to LDH released from cells treated with medium-only, free BAR, 
and BAR-EFs (P ≤ 0.0001). 
Oxidative DNA Damage: AP sites were determined as oxidative stress 
marker for cells treated with free BAR or BAR-EFs (1.3 or 3.4 µM). As shown in 
Figure 4.11, free BAR or BAR-EF treated (1.3 or 3.4 µM) cells demonstrated 
negligible changes in AP sites relative to medium-only treated cells. While cells 
treated with 2 mM H2O2 exhibited a significant increase of AP sites relative to free 
BAR, BAR-EFs (1.3 or 3.4 µM) and medium-only treated cells (***, P ≤ 0.001). 
103 
 
Results suggested that neither free BAR nor BAR-EFs (1.3 or 3.4 µM) induced 















Figure 4.10 (A) The hemolytic activity of free BAR or 10:90 PLGA:PEO BAR-EFs 
(1.3, 3.4 µM) was assessed after administration to sheep erythrocytes for 3 hr. 
Free BAR and BAR-EFs showed negligible hemolysis for sheep erythrocyte 
relative to release from H2O-treated cells (****, P ≤ 0.0001). (B) Free BAR and 
BAR-EFs were non-toxic, relative to cells treated with DMSO (****, P ≤ 0.0001). 
(C) BAR-EFs (3.4 µM) treated cells showed decreases in ATP levels relative to 
medium-only treated cells, while TIGK cells treated with staurosporine 
demonstrated lower ATP levels than the cells treated with medium-only, free BAR, 
and BAR-EFs (****, P ≤ 0.0001). (D) None of free BAR or BAR-EF (1.3, 3.4 µM) 
treated cells released a significant level of LDH relative to medium-only treated 
cells. Staurosporine-treated cells demonstrated significantly elevated LDH levels 





Figure 4.11 Amount of AP sites per 100000 bp of genomic DNA obtained from 
TIGK cells treated with free BAR or BAR-EFs (1.3, 3.4 µM). Level of AP sites of 
cells treated with free BAR or BAR-EFs (1.3, 3.4 µM) demonstrated negligible 
changes relative to medium only treated cells. However, TIGK cells treated with 2 
mM H2O2 demonstrated significantly (***, P ≤ 0.001) higher level of AP sites 
relative to control, free BAR and BAR-EFs (1.3, 3.4 µM). Data represent the mean 
± standard deviation (n=3) of three independent runs. 
Discussion 
Periodontal disease is one of the most widespread oral diseases among the 
adult population worldwide, resulting in degradation of the supporting tissues of 
the teeth, and contributing to dental and systemic diseases41,161. Porphyromonas 
gingivalis, both a prominent component of the oral microbiome and a successful 
colonizer of the oral epithelium162, has been suggested to function as a keystone 
pathogen, as it facilitates a change in both the amount and composition of the 
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normal oral microbiota and creates dysbiosis between the host and dental 
plaque42. The initial species-specific supragingival interaction between Pg and Sg 
is considered to initiate the biofilm formation process163 and is mediated by 
interaction of the Mfa1 protein of Pg and the SspB polypeptide of Sg164. Since this 
interaction is an initial event that promotes Pg colonization of the oral cavity, it 
represents an ideal point for therapeutic intervention.  
A discrete motif of the SspB polypeptide designated, SspB Adhering Region 
(BAR), was identified164, and a synthetic peptide encompassing this motif potently 
limited Pg colonization both in vitro and in vivo. Despite this, BAR was shown to 
be less effective against well-established and complex biofilms, requiring 
prolonged exposure to be effective. The objective of this work was to synthesize 
and characterize EFs as a new dosage form to deliver the bioactive molecule, 
BAR, against biofilm formation for durations relevant to oral administration. We 
hypothesized that BAR-incorporated EFs, would provide a new platform to enable 
the short-term release of therapeutically relevant concentrations of BAR to be 
applied twice daily. Moreover, we hypothesized that BAR release from EFs may 
be modulated by changing the hydrophobic polymer type and PEO blend ratios.  
Local drug delivery vehicles in the form of films165, strips166,167, and wafers168 
have been applied to periodontal disease, where the subgingival pockets act as a 
natural reservoir for these drug-loaded carriers. However, the methods used to 
fabricate these dosage forms include solvent casting, melt spinning and direct 
milling methods, which often prove to be labor intensive, time consuming, and 
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expensive. In contrast, electrospinning may provide a simple-to-use, time and cost-
efficient process.  In addition, EFs offer several advantages relative to other 
dosage forms including the large surface-to-volume ratio, which can provide 
increased contact between the encapsulated bioactive molecule and the 
surrounding medium and tissue environment; small diameter fibers for efficient 
drug release; the ability to tailor different drug release profiles; and mechanical 
stability169. Here we envisioned that designing EFs targeted to the oral cavity may 
provide a new dosage form in which to administer BAR, relative to the 
administration of free BAR, and may provide a mechanism to improve therapeutic 
outcomes by increasing the localized concentration of BAR. Long-term, we 
envision BAR-EFs may be administered as dental strips or in gel form to degrade 
and avoid surgical removal after application. 
To date, polymeric EFs have been used as delivery vehicles in several 
biomedical applications including wound dressing materials158, tissue 
regeneration159,160, and as drug delivery vehicles for bioactive molecules, 
antimicrobial agents97, anti-inflammatory drugs170, and anesthetics171. Moreover 
PLGA fibers have provided cell scaffolds160, and have been combined with other 
polymers including PCL and PLA to deliver traditional antibiotics such as 
doxycycline97 and metronidazole for the localized treatment of periodontitis98,172. 
However, hydrophobic-only fibers have exhibited delivery limitations such as poor 
wettability, combined with inadequate flexibility and stiffness properties. Despite 
this, these and other more biodegradable fiber types such as polydioxanone and 
PLA:PCL/Gelatin fibers incorporating ciproflaxin and tetracycline respectively, 
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have significantly inhibited periodontal pathogens without affecting the growth of 
beneficial commensal oral bacteria173,174.  
Given this favorable potential, our goal was to fabricate and compare non-
blended (hydrophobic-only polymer fibers) with blended BAR-incorporated EFs 
using a uniaxial electrospinning approach.  We initially formulated 1% w/w fibers 
(BAR/polymer), resulting in a theoretical loading of 10 g BAR per mg of polymer, 
a concentration shown in our previous work to inhibit biofilm formation. All resulting 
EFs demonstrated high F-BAR loading and encapsulation efficiency, ranging from 
4.7 to 9.4 µg/mg and 47-90%, respectively. However, the release kinetics of the 
non-blended PLGA, PLLA, and PCL fibers revealed minimal release of the total 
incorporated F-BAR over 24 hr. We attributed the high hydrophobicity of the non-
blended PLGA, PLLA, and PCL fibers to minimal eluate penetration past the 
outermost fiber layer. Moreover, hydrophobic sequences in the BAR peptide may 
promote hydrophobic F-BAR interactions with the purely hydrophobic non-blended 
fibers, resulting in lower release.  
 While hydrophobic polymers have been used in numerous applications 
outside of the oral cavity, to obtain time frames of release relevant to oral delivery 
(once or twice daily), we sought to modulate fiber hydrophobicity with the addition 
of hydrophilic PEO in ratios (PLGA/PLA/PCL:PEO 40:60, 20:80 and 10:90). 
Previous work has shown that blending hydrophobic polymers with more 
hydrophilic polymers increases the release of biological molecules such as 
lysozyme, while maintaining protein activity175. In addition, many studies have 
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shown that the addition of PEO to protein solutions can improve protein stability175-
177. Moreover, recent studies demonstrated that incorporation of PEO with 
hydrophobic fibers increased the pore formation and fiber weight loss with rapid 
degradation rate relative to non-blended fibers178,179. 
By increasing the fiber hydrophilicity with the addition of PEO (PLGA:PEO 
40:60, 20:80 and 10:90), BAR release was significantly improved in the blended 
fibers. This is in agreement with studies that have shown that by introducing 
hydrophilic PEO into fiber formulations, the physical and mechanical properties of 
the fiber change, while providing the ability to tune encapsulant (e.g., BAR) 
release178. While hydrophobic polymers provide structural integrity to the scaffold, 
the PEO makes it more porous, enabling the release of the hydrophilic BAR 
peptide. Moreover, by incorporating PEO in EFs our initial goal was to formulate 
EFs that would rapidly degrade and release BAR, to avoid removal of EFs after 
administration.  In addition, hydrophilic molecules have been shown to have more 
affinity and compatibility with PEO, explaining the initial burst release presented by 
the blended fibers. Last, we postulate that in addition to materials properties, the 
electrospinning process itself can affect encapsulant location within 
hydrophobic:hydrophilic blended fibers, prompting variable release kinetics. 
During electrospinning, the electric field may promote F-BAR aggregation close to 
the fiber surface, due to charge repulsion180. This localization, potentially resulting 
in the release of F-BAR only near the fiber surface, may contribute to the burst 
release observed in all blended fiber formulations.  
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Among the hydrophobic polymers utilized, PLGA formulations 
demonstrated the highest release at early time points, followed by PLLA and PCL 
formulations. We propose that PLGA fibers demonstrate the highest release due 
to its amorphous and less hydrophobic properties, relative to the more hydrophobic 
PLLA and PCL polymers. Relative to PLGA:PEO and PLLA:PEO blends, we 
propose that PCL:PEO fibers demonstrated the least release due to its crystalline 
and slightly more hydrophobic features. 
The PLGA:PEO (10:90) fibers exhibited 88% encapsulation efficiency and  
90% release of F-BAR, the highest among all the blended and non-blended 
formulations within the first 2 hr, with PLLA:PEO (10:90) exhibiting 65% release, 
and PCL:PEO (10:90) releasing 45% in the same time frame. Negligible quantities 
of F-BAR were released after 24 hr. Taking both encapsulation efficiency and 
release properties into consideration, PLGA:PEO (10:90) was selected to evaluate 
biofilm efficacy. BAR-incorporated PGLA:PEO 90:10 EFs were evaluated to inhibit 
two-species biofilm formation and disrupt pre-existing biofilms, against an 
equimolar concentration of free BAR. BAR-EFs potently inhibited biofilm formation 
(IC50 = 1.3 µM) in a dose-dependent manner (Figure 4.7). In addition, BAR-EFs 
efficiently disrupted pre-existing dual-species biofilms (IC50 = 2 µM) (Figures 4.8 
and 4.9B). 
The fibers fabricated in this study were formulated with 1% w/w 
BAR:polymer. As such, they demonstrated high encapsulation efficiency spanning 
60-90%, with burst release in the first 2 hr and minimal release thereafter. To 
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achieve the IC50 of BAR (4 µg/mL) at every time point over the duration of 24 hr, 
loading capacity must be increased. However, previous work has shown that using 
a theoretical loading higher than 1 % w/w100 via uniaxial blended spinning process 
may still result in significant initial burst release. To overcome burst release, 
optimize the release kinetics, and maintain peptide stability, techniques like co-
axial or emulsion electrospinning may be adopted in future work181,182. Several 
studies have used co-axial electrospinning to sustain the release of bioactive 
molecules. Moreover, the bioactivity of biological agents may also be maintained 
since it is not incorporated into the polymer/solvent solution prior to 
electrospinning183. Alternatively, emulsion electrospinning may help to 
encapsulate the aqueous agents within the core, to provide sustained and 
incremental release of the encapsulant182. These advancements may be helpful in 
formulating prolonged-release fiber therapeutics for periodontitis as an intra-
pocket delivery system, where the fibers can be immobilized in the subgingival 
pocket for a longer duration of time.  
Targeted drug delivery is required to achieve effective therapy against 
periodontal diseases. Thus, different drug delivery vehicles like gels, 
nanoparticles, films and fibers have been developed to combat oral diseases28. 
However, antibiotic side effects, desired  release profiles, and non-specific 
targeting are still limitations facing antibiotic184, anti-inflammatory185 and 
antiseptic186 loaded polymeric gels currently available to prevent and treat chronic 
periodontitis.  Moreover, even with these formulations, high loading efficiency, 
sterility, and high cost are challenges that need to be addressed.  In comparison, 
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delivery vehicles that enable the specific targeting of periodontal keystone 
pathogens may provide a path to develop a novel formulation that exerts potent 
prophylactic or therapeutic effect via specific interactions, in addition to providing 
adhesive properties and localized release with minimal side effects.  
Our results demonstrated the feasibility, versatility and straightforward 
approach of electrospinning EFs that release therapeutically-relevant 
concentrations of BAR, to specifically target periodontal pathogens. Fibers with 
increasing PEO content significantly enhanced F-BAR release within 4 hr, while 
the most promising 10:90 PLGA:PEO formulation provided 95% F-BAR release 
after 4 hr, inhibited biofilms in a dose-dependent manner (IC50 = 1.3 M), and 
efficiently disrupted dual-species biofilms (IC50 = 2 M). Our results suggest that 
BAR-incorporated EFs may provide an alternative and specifically-targeted rapid-
release platform to inhibit and disrupt dual-species biofilms, that we envision may 
be applied once or twice daily to exert prophylactic effect in the oral cavity without 
the need to remove the fibers after application. We acknowledge that in vivo 
delivery of BAR-EFs has challenge such as complex biofilm not be reflected the 
more ideal environment in vitro study. Thus, future studies will be focused on 
developing targeted BAR-EFs to overcome in vivo applications challenges and  
optimizing the release kinetics of BAR from blended EFs for more sustained 






ASSESSMENT OF TARGETED BAR-ENCAPSULATED NPS AGAINST ORAL 
BIOFILMS 
Introduction 
Polymer NPs have been applied to a variety of applications in dentistry and 
have demonstrated success in reducing the number of intracellular bacteria 
relative to the administration of free antibiotic, and in penetrating alveolar bone 
trabeculae, underlying connective tissue, and even the periodontal pocket areas 
below the gum, due to the small NP size.  Other NPs have  targeted gingival cells 
in order to deliver higher local concentrations of antibiotic for a prolonged 
period85,86,127,152. Polymer NPs have a variety of attributes including the ability to 
encapsulate both hydrophilic and hydrophobic cargos and to provide sustained-
release of these encapsulated active agents. Moreover, surface-modification of 
NPs can increase efficaciousness by targeting active agent directly to impacted 
sites. Through surface-modification, polymer NPs may also enhance tissue 
adherence, resulting in the delivery of higher localized concentrations of drug, due 
to their inherent mucoadhesive properties, via hydrogen bonding, polymer 
entanglement with mucins and hydrophobic interactions, or through coating with 
mucoadhesive compounds like chitosan55,56,61,66,141,142.        
114 
 
Despite the variety of mucoadesive polymer NPs used to treat oral biofilms, 
there is currently a scarcity of drug delivery vehicles that enable specific and 
prolonged delivery of specifically-targeted biologic active agents to the oral cavity.    
Previous work from our groups has demonstrated that BAR-encapsulated 
NPs may improve efficacy and longevity in the oral cavity, relative to free BAR143. 
In addition, BAR-modified NPs delivered a high localized concentration of BAR 
peptide and improved BAR effectiveness through multivalent interactions with Pg, 
relative to administration of free BAR in in vitro and murine periodontitis 
models95,96. While BAR-encapsulated and BAR-modified NPs demonstrated 
significant promise to prevent and treat oral biofilms, retention in the oral cavity is 
known to be a challenge for mobile NP delivery vehicles. Free NPs may be 
removed by salivary flow, resulting in lower retention in the oral cavity, 
necessitating higher concentrations of delivery to maintain efficacy.  
Previous studies have sought to address this challenge by integrating 
carboxymethyl cellulose (CMC)123, poly acrylic acid (Carbopol)187, polyethylene 
glycol (PEG)92,188, polyvinyl alcohol (PVA)189 or polyvinyl pyrrolidone (PVP)189,190 
into NPs to localize and maintain active agent for longer durations in the oral cavity. 
Another study developed chitosan-coated PLGA NPs to promote mucoadhesion 
to the buccal surface to localize lovastatin and tetracycline within the oral cavity. 
PLGA-lovastatin-chitosan-tetracycline nanoparticles demonstrated higher 
localized concentration of tetracycline with sustained-release for a prolonged 
period due to the mucoadhesive properties of the NPs and the slow degradation 
115 
 
rate of chitosan 90. In addition, recently, minocycline-loaded poly(ethylene glycol)-
poly(lactic acid) (PEG–PLA) NPs were surface-modified with RGD peptides to 
target gingival epithelial cells. Targeted minocycline NPs demonstrated potent 
anti-periodontitis activity relative to non-targeted NPs and free minocycline in dogs. 
Moreover, RGD-modified minocycline NPs delivered a higher localized 
concentration of minocycline to the gingiva and retained the effective concentration 
for a longer time, relative to minocycline-loaded NPs94. 
While a variety of broadly active mucoadhesive molecules have been used 
to increase adhesion and retention in the oral cavity, an alternative approach is to 
exploit known protein-protein interactions that drive interspecies coaggregations 
between oral organisms to promote adhesion to, and target specific niches in the 
oral microbiome. For example, recent studies have demonstrated that 
coaggregation factor A (CafA) is a cell surface protein of Actinomyces oris that 
promotes Actinomyces/Streptococcus coaggregation191. Thus CafA represents an 
ideal targeting molecule to promote NP adherence to Sg and specifically deliver 
active agent to this niche. We propose that NP modification with CafA will enhance 
targeting to streptococcal cells, an initial niche of Pg in the oral cavity54. By 
targeting NPs to this niche, we hypothesize that CafA-modified BAR-encapsulated 
NPs will deliver higher localized concentrations of BAR and will be retained for a 




Materials and Methods 
Peptide Synthesis 
 BAR peptide is comprised of residues 1167 to 1193 of the SspB (Antigen 
I/II) protein of Sg with the sequence NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-
COOH112. To facilitate conjugation of BAR to the NP surface, the peptide was 
synthesized with an N-terminal biotin. Biotinylated BAR was subsequently 
attached to NPs that had been modified with palmitylated avidin, as previously 
described95. To enable peptide quantification and detection, some preparations of 
BAR were modified such that the epsilon amine of the underlined lysine residue of 
BAR was covalently reacted with 6-carboxyfluorescein to produce fluorescent BAR 
(F-BAR). All preparations of peptides were synthesized by BioSynthesis, Inc. 
(Lewisville, TX) and were guaranteed to have greater than 90% purity via RP-
HPLC analysis.  
CafA Synthesis  
CafA synthesis was done in the laboratory of Dr. Donald Demuth by Jinlian 
Tan. Genomic DNA of Actinomyces oris (ATCC 43146) was isolated from 10 mL 
of an overnight culture using the Wizard Genomic DNA purification kit (Promega, 
Madison WI) as specified by manufacturer. The cafA gene was amplified by PCR 
using 200 ng of genomic DNA as the template and 30 pmol each of the following 
primers: Forward: 5’- AAG GAT CCC TGA GGC CGT TCA -3’; Reverse: 5’- CCG 
GAA TTC TAC GAC TTG CGG TTG GAG-3’. PCR amplification was conducted 
by denaturation at 94°C for 2 min, annealing of primers and template at 63°C for 
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30 s, strand extension at 72°C for 2 min 45 s, for 30 cycles followed by a final 
extension cycle at 72oC for 5 min. 
The PCR product was subsequently electrophoresed in 1% agarose at 90 
V for 40 min and the cafA band was excised and purified using the gel purification 
kit (Qiagen). The purified cafA DNA (1 g) and a sample of the pGEX-6p-1 
expression vector (0.5 g) were digested with BamHI and EcoRI overnight at 37°C. 
Prior to ligation, 50 µL of the digested vector were dephosphorylated with 4 µL calf 
intestinal alkaline phosphatase (NEB) at 37°C for 30 min. Subsequently, 3 µL of 
protease K were added and incubated for 30 min at 50°C to terminate the reaction. 
The vector and cafA fragments were purified using the DNA clean and 
concentrator kit (Zymoresearch) and ligated with T4 ligase. Ligation reactions 
comprised three µL vector, 5 µl cafA fragment, 1 L 10x ligase buffer and 1µL T4 
ligase.  
The ligation mixture was initially transformed into E. coli Top 10. Fifty µL of 
competent E. coli Top 10 were incubated with 5 µL of ligation mixture on ice for 30 
min., then the sample was heat shocked at 42°C for 45 s and placed on ice for 2 
min. Two hundred µL of SOC media were added, the sample was incubated at 
37°C for 1 hr and plated on LB agar. After overnight incubation at 37°C, single 
colonies were selected and cultured in 5 ml LB broth supplemented with 100 g 
ampicillin. Plasmid purification was carried out using the mini prep kit (Qiagen) and 
the cafA insert was excised and confirmed by sequencing. 
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For CafA expression, the purified cafA plasmid was transformed into E. coli 
BL21 using the transformation protocol described above.  After selecting and 
confirming the appropriate transformant, 400 mL of LB broth was inoculated with 
10 mL of an overnight culture and incubated to OD600nm of 0.5. Protein expression 
was induced by the addition of 0.5mM IPTG and the culture was then incubated at 
18°C for 17h. After centrifugation at 6000 rpm, the cell pellet was suspended in 40 
mL 50mM Tris, 100mM NaCl, 1mg/ml lysozome,10ug/ml Dnase I, protease 
inhibitor cocktail, 10mM CHAPS, incubated overnight at 4°C, then for an additional 
2 hr at 25°C.  The cell suspension was then sonicated for 2 min on ice. 
CafA purification was carried out with the Pierce GST Spin Purification Kit 
(Thermo Fisher). Seventeen mL of crude cell lysate were bound to the GST column 
for 2 hr at room temperature and the column was then centrifuged to remove 
unbound protein according to the specifications of the manufacturer. After washing 
the column with loading buffer, the GST tag was cleaved by the addition of 50 µL 
precision protease (GE Health) and overnight incubation at 4°C. Released CafA 
was then collected by centrifugation. The sample was then sequentially dialyzed 
against 30 mM, 20 mM, and 10 mM Tris for 2 hr each.  CafA purity was determined 
by PAGE gels and protein concentration was determined using the BCA assay 
(Pierce). 
Synthesis of CafA-Palmitate 
 NPs were conjugated with CafA-palmitate as previously described96,122,146.  
Briefly, 8 mg of CafA were dissolved in 1.2 mL of 2% (w/v) sodium deoxycholate 
119 
 
(NaDC) in PBS and warmed to 37°C. CafA was then reacted with 14-fold molar 
excess of the palmitic acid-N-hydroxysuccinimide ester (PA-NHS; Sigma-Aldrich, 
St Louis, MO, USA).  Palmitic acid-N-hydroxysuccinimide ester was dissolved in 
2% (w/v) NaDC at 0.5 mg/mL, and sonicated until well-mixed. Eight hundred 
microliters of the PA-NHS solution were added in drops to the reaction vial 
containing CafA and allowed to react overnight at 37°C. The reaction solution was 
then dialyzed in 1.2 L of 0.15% (w/v) NaDC in PBS at 37°C using a 3,500 molecular 
weight cut-off dialysis tube to remove free PA-NHS. After overnight dialysis at 
37°C, CafA-palmitate was transferred to a storage vial and stored at 4°C until use. 
CafA Surface-Modified Nanoparticle Synthesis 
CafA surface-modified NPs were synthesized using a previously described 
single-emulsion technique88,121. PLGA with a 50:50 monomer ratio and 0.55–
0.75 dL/g inherent viscosity, was purchased from LACTEL®. Briefly, 100 mg PLGA 
was dissolved in 2 mL dichloromethane (DCM) overnight. The following day, 2 mL 
of a 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 mL of 4 mg/mL 
CafA-palmitate. The 2 mL PLGA/DCM solution was added dropwise to 4 mL 
PVA/CafA-palmitate solution while vortexing. The NP solution was added to 50 mL 
of 0.3% PVA for 3 hr to evaporate residual DCM. After evaporation, the NP solution 
was centrifuged at 13,000 rpm (20,442 x g) at 4°C. Supernatant was discarded, 
and the NPs were washed two times with deionized water (diH2O) by 
centrifugation at 13,000 rpm (20,442 x g) at 4°C to obtain NPs with sizes less than 
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~200 nm. After washing, CafA surface-modified NPs were suspended in 5 mL of 
diH2O, frozen at -80°C, and lyophilized.   
Surface-modified NPs encapsulating the fluorescent dye Coumarin 6 (C6) 
or F-BAR were synthesized for binding, loading and controlled release studies. C6-
containing NPs were synthesized using an oil-in-water (o/w) single-emulsion 
technique122,192.  Briefly, C6 was dissolved in 200 μL dichloromethane (DCM) 
overnight at a concentration of 15 μg/mg PLGA. In parallel, 100 mg of PLGA 
crystals was dissolved in 2 mL of DCM overnight. The following day, the 
PLGA/DCM solution was vortexed while adding C6 DCM solution and was 
subsequently sonicated. Next, 2 mL of the PLGA/DCM/BAR solution was added 
dropwise to mixture of 2 mL of 5% (w/v) polyvinyl alcohol (PVA) and either 2 mL 
of 5 mg/mL avidin-palmitate or 2 mL of 4 mg/mL CafA-palmitate while vortexing 
and was subsequently sonicated. Residual DCM was evaporated by adding the 
NPs solution to 50 mL of 0.3% PVA for 3 hr while mixing. The same procedures 
as described above were conducted to synthesize blank surface-modified NPs.  
F-BAR-encapsulated CafA-modified NPs were synthesized similarly using 
a double-emulsion technique. F-BAR was dissolved in 200 μL Tris EDTA buffer at 
a concentration of 43 µg BAR/mg PLGA and protected from light during 





NP Characterization: NP Morphology, Size, CafA Conjugation, Controlled 
Release  
 Unhydrated NP morphology, diameter, and size distribution were 
determined using scanning electron microscopy (SEM, XL-30 ESEM-FEG SEM, 
FEI Company, USA). Lyophilized NPs were mounted on carbon tape and sputter 
coated with a thin layer of gold/palladium. Average diameters of 500 particles were 
determined from SEM images (n=3) using image analysis software (ImageJ, 
National Institutes of Health, version 1.5a, ImageJ.nih.gov). Dynamic light 
scattering and zeta potential analyses were performed to determine the 
hydrodynamic diameter and surface charge of hydrated NPs. The unhydrated and 
hydrated diameters of NPs are typically assessed to establish the size 
characteristics within different conditions of dry storage and more physiologically 
relevant aqueous environments. Briefly, a 1 mg/mL sample of CafA-modified 
PLGA NPs in diH2O was prepared. After vortexing and sonication, samples were 
diluted at a 1:50 ratio in diH2O. One mL was aliquoted to the cuvette for analysis 
(Malvern, Malvern, UK (Zetasizer Nano ZS90), courtesy of Dr. Martin O’Toole, 
Univ. of Louisville) to measure dynamic light scattering and zeta potential with 
Zetasizer Nano software. Samples were run in triplicate, using a refractive index 
of 1.57 for PLGA, absorption coefficient of 1, and water refractive index of 1.33.  
To measure the amount of CafA that was conjugated to the NP surface the 
microBCA assay was conducted and compared to a CafA standard95,146.  After 
conjugation, NPs were centrifuged and washed twice with diH2O to remove 
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unbound CafA from the formulated NPs. NPs were then suspended in PBS:DMSO 
(1:99) to create a 1 mg/mL NP solution and the resulting samples were transferred 
to a microtiter plate in triplicate. Total NP-associated absorbance was determined 
using Victor3 Multilabel spectrophotometer (562 nm), and the concentration of 
CafA was determined from a standard curve of known CafA95.  
For CafA-modified F-BAR-encapsulated NPs and unmodified F-BAR-
encapsulated NPs, in vitro release was measured by gentle agitation of NPs in 
PBS (pH 7.4) at 37ºC. At fixed time points (1, 2, 4, 8, 24 hr), samples were collected 
and the amount of F-BAR released from the NPs was quantified by measuring 
fluorescence (488/518 nm excitation/emission).  
Stability of the CafA-NP Interaction  
The stability of the CafA palmitate interaction with the NP surface was 
tested by assessing the release of the CafA ligand from the NP surface with 
respect to time. Similar to loading experiments, the CafA concentration was 
determined using microBCA assay by measuring absorbance at 562 nm95,96 and 
comparing to a standard curve of CafA. 
Growth of Bacterial Strains 
 Pg (ATCC 33277) was grown in Trypticase soy broth (Difco Laboratories 
Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 1 µg/mL 
menadione, and 5 µg/mL hemin. The medium was reduced for 24 hr under 
anaerobic conditions (10% CO2, 10% H2, and 80% N2) and Pg was subsequently 
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inoculated and grown anaerobically for 48 hr at 37°C. Sg DL-1 was cultured aero-
bically without shaking in brain-heart infusion broth (Difco Laboratories Inc.) 
supplemented with 1% yeast extract for 16 hr at 37°C111-113. 
Time-Dependent Binding of CafA-Modified NPs to Sg  
The binding of CafA-modified NPs was compared to NPs that were modified 
with the same density of a non-specific positively-charged protein, avidin, through 
similar palmitic acid chemistry. Sg was harvested from culture and the bacterial 
concentration was determined by measuring the O.D. at 600 nm from twenty-fold 
diluted cultures of Sg. Sg cells were plated and then incubated with CafA-modified 
and avidin-modified NPs. One hundred microliters of 0.2 OD Sg were added to the 
96-well culture plate and incubated at 4°C overnight. The next day, wells were 
blocked for non-specific binding with 300 µL of 0.3% bovine serum albumin (BSA) 
for 1 hr. After washing three times with 1x phosphate buffer saline with 0.05% 
Tween (PBST), 100 µL of CafA-modified C6 NPs (0.25 mg/mL), avidin-modified 
C6 NPs (0.25 mg/mL) and PBST were added to wells in triplicate, and then 
incubated on a rocker platform for 1 hr. After washing, the quantity of CafA-
modified and avidin-modified C6 NPs binding to Sg was determined by measuring 
the fluorescence (485/520 nm excitation/emission) after subtraction of the control, 
in which Sg was incubated with PBST only, and this reading was considered as 
time zero with 100% binding. One hundred µL of PBST were added to each well 
and incubated with gentle agitation. After 1, 2, 4, 8, 12 and 24 hr the quantity of 
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CafA-modified and avidin-modified C6 NPs bound to Sg was determined by 
measuring fluorescence. 
Results     
Quantification of the Total CafA Payload of CafA-Modified NPs 
The amount of CafA bound to the NP surface directly correlated with the 
input concentration of CafA, and the maximum surface density of CafA was 
achieved by increasing the input concentration of CafA as shown in Figure 5.1.  A 
maximum density of 36 µg CafA/mg NP was incorporated on the PLGA NP surface 
using an input concentration of 80 µg CafA per mg NP, yielding 45% conjugation 







Figure 5.1 The total amount of CafA bound to the surface of PLGA NPs was 
determined using the microBCA assay. The amount of incorporated CafA on NP 
surface is directly correlated to the input amount of CafA during fabrication.  
CafA-modified Adhesion and Retention to Sg  
To determine how long CafA-modified NPs remain bound to Sg, 
streptococcal cells were immobilized and CafA-modified NPs or avidin-modified 
NPs were incubated with Sg for 1 hr. The quantity of CafA-modified and avidin-
modified C6 NPs initially bound to Sg after this hour was considered “time zero” 
and was set to the maximum (100%) binding achievable. The quantity of CafA-
modified NPs and avidin-modified NPs retained (remaining bound) after 1, 2, 4, 
and 8 hr were determined, and compared to the amount bound during the initial 1 
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hr period. As shown in Figure 5.2, after 1 hr, 5.7 µg of CafA-modified NPs were 
bound to Sg, relative to 2.5 µg of the control, avidin-modified NP group, resulting 
in a 2.3-fold increase in binding, due to CafA surface modification. After 8 hr, 3.7 
µg of CafA-modified NPs and 1.4 µg of avidin-modified NPs were bound to Sg, 
resulting in a 2.5-fold increase in binding (Figure 5.2A). This corresponded to 65% 
of CafA-modified NPs and 56% of non-specific avidin-modified NPs bound, 
suggesting that surface modification with CafA strongly impacts NP adhesion and 
retention (Figure 5.3B).   In addition, CafA-modified NPs demonstrated stronger 
initial binding and a similar but less pronounced decrease in binding with respect 
to time, relative to avidin-modified NPs.  
 
Figure 5.4 (A) CafA-modified C6 NPs initially (t = 0) bind to Sg with 2.3-fold greater 
concentration (5.7 ug/mL), relative to avidin-modified C6 NPs (2.5 µg/mL) and 
maintain a 2.5-fold increase in binding (3.7 µg/mL) after 8 hr, relative to avidin-
modified C6 NPs (1.4 µg). (B) 65% of CafA-modified C6 NPs retain binding to Sg 




Quantification of BAR Release  
To assess BAR release from the NPs, the fluorescence of supernatant from 
1, 2, 4, 8, 24 hr release time points was measured and compared to a known 
standard of F-BAR in PBS. Loading experiments demonstrated that both 
unmodified and CafA-modified PLGA NPs highly encapsulated BAR with 16.95 ± 
0.8 and 15.73 ± 1.9 µg of BAR per mg of NP, respectively, corresponding to 
encapsulation efficiencies of 39.4 and 36.5% (Table 5.1). Release experiments 
demonstrated that 10.3 µg/ml of encapsulated BAR was released from CafA-
modified BAR-encapsulated NPs, while 15.5 µg/mg of encapsulated BAR was 
released from unmodified BAR-encapsulated NPs within 24 hr (Figure 5.3).  









Unmodified NPs 43 16.95 ± 0.8 39.4 






Figure 5.5 (A) Cumulative release of BAR as a function of mass (µg BAR per mg 
NP) and (B) percent of total BAR loaded over 24 hr.  
Stability of the CafA-NP Interaction  
The stability of CafA binding to the NP surface was assessed by incubating 
CafA-modified NPs with agitation in 1x PBS at 37°C for 24 hr. Quantification of 
CafA release into the supernatant after 1, 2, 4, 8, and 24 hr was evaluated using 
the microBCA assay, and the percent of CafA retained on the NP surface relative 
to the amount loaded was determined. Over 82 ± 3% of the initial CafA remained 
conjugated to PLGA NPs after 24 hr indicating a stable interaction with the NP 




Figure 5.6 Percent of CafA retained on the PLGA NP surface after 24 hr.  
Thus far we have established this approach to fabricate CafA-modified 
BAR-encapsulated NPs with a high and stable surface density of CafA. CafA-
modified NPs highly encapsulated BAR peptide with more gradual and increased 
release, relative to unmodified BAR NPs. These results suggest that CafA-
modified NPs may be a promising platform to maintain BAR concentration in the 
oral cavity for 12 to 24 hr for once or twice daily application. In addition, studies 
demonstrate the utility of modifying BAR-encapsulated NPs with CafA to achieve 
efficient binding and retention to Sg for at least 8 hr, relative to avidin-modified 
NPs.  
The next steps we envision are to assess the functional activity of CafA-modified 
BAR-encapsulated NPs against novel 3D dental mimetic tissue with dual-species 




OVERALL DISCUSSION AND CONCLUSION 
Periodontal disease is a group of chronic inflammatory diseases that is 
globally prevalent, affecting ~46% of U.S adults and 30-50% of people globally. 
Porphyromonas gingivalis has been identified as a “keystone” pathogen involved 
in the initiation and progression of periodontal inflammatory disease, by disrupting 
host-microbe homeostasis and inducing population changes in the subgingival 
biofilm108. This disruption and colonization is initially prompted by association of 
Pg with oral streptococci in the supragingival niche, and is thus an ideal target for 
therapeutic intervention9.  
Previous work in our groups has shown that a region of the streptococcal 
antigen denoted BAR inhibits Pg/Sg interaction and biofilm formation both in vitro 
and in a murine model of periodontitis111-113. Moreover, recent studies 
demonstrated the potential of BAR surface-modified PLGA nanoparticles to deliver 
a high localized concentration of peptide to subgingival niches95. While surface-
modified NPs were shown to potently inhibit biofilm formation via multivalency, the 
development of a formulation that can release BAR peptide, within a time frame 
relevant to oral delivery, had not been investigated.   
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Moreover, the potential of a new dosage form that might increase the 
convenience and flexibility of administrating a specific peptide into the oral cavity 
had not been explored by our groups. With this in mind, the aims of this dissertation 
were to translate our previous in vitro BAR-modified NP work to a murine model of 
periodontitis95, investigate the potential of novel BAR-encapsulated NPs to inhibit 
and disrupt biofilm formation for prolonged durations relevant to oral delivery, and 
develop rapid-release BAR-EFs that may, in future work, be applied twice daily to 
release therapeutically relevant concentrations of BAR in the oral cavity. 
To date, a variety of groups have developed polymeric delivery vehicles to 
improve traditional prevention and treatment approaches to periodontal 
diseases86. However, polymeric delivery vehicles have been primarily developed 
to deliver antibiotics85,86,90,152,153 for prolonged durations, and to decrease antibiotic 
dose, administration frequency, and associated adverse effects. However, 
antibacterial resistance and non-specificity still remain challenges to effectively 
eradicate initial and recurrent biofilms, pathogen resistance, and associated 
diseases35,37,107. 
While recent studies have demonstrated some success using various 
polymeric NPs in dental pathogen murine models85,86, these studies have focused 
on targeting antibiotic NP formulations to epithelial cells with gingival targeting 
RGD peptides. Results from these studies indicated that NP surface-modification 
improved NP attachment to epithelial cells, maintaining antibacterial (i.e., 
minocycline) concentrations in gingival fluid for prolonged durations and improved 
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therapeutic activity relative to unmodified NPs94. Other studies have similarly 
sought to use RGD94, or more general bioadhesive molecules such as 
chitosan124,126 or dimethyl-octyl ammonium134, to obtain improved localization and 
adhesion to the dental surface. Strong mucoadhesive properties and adhesion to 
the tooth surface124  were demonstrated for antibacterial NPs modified with these 
agents. 
Polymeric electrospun fibers have been used as delivery vehicles in several 
biomedical applications including wound dressing materials158, tissue 
regeneration159,160, and as drug delivery vehicles for bioactive molecules, 
antimicrobial agents193, anti-inflammatory drugs170, and anesthetics171. Moreover 
fibers have provided cell scaffolds  with PLGA EFs160, in combination with PCL 
and PLA to deliver doxycycline193 and metronidazole98. 
Specific to oral delivery, electrospun fibers have been investigated for 
antibiotic, anti-inflammatory and analgesic delivery, periodontal tissue 
regeneration, and  to act as implantable drugs and growth factor-releasing 
scaffolds that help repair surgical sites97,160,170,171. Previous studies demonstrated 
that metronidazole-loaded PLA or PCL fibers showed sustained-release of 
metronidazole with potent antibacterial activity, however poor wettability and 
stiffness limited the use of PLA and PCL alone without hydrophilic fiber blend for 
local periodontitis treatment98,172. In addition, PLA:PCL/Gelatin fibers containing 
tetracycline demonstrated significant inhibition of oral biofilms in vitro, suggesting 
that tetracycline-loaded fibers may act as potent antibacterial implant for dental 
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application; however, non-specific activity of tetracycline may affect the growth of 
commensal beneficial oral bacteria174.  
In comparison with limited and mostly non-specific approaches to prevent 
or treat periodontal diseases, the goal of this work was to incorporate a pathogen-
specific biological active agent within a NP surface modification or encapsulation, 
to exploit the specific and adhesive interactions between two bacteria known to 
initiate the process of periodontal infections. We showed that not only can this 
specific peptide target biofilm interactions, but that by conjugating BAR to a NP 
surface or encapsulating BAR within PLGA NPs or EFs, we can achieve safe and 
enhanced potency, attributed to multivalency and prolonged activity, in a murine 
model of infection and in vitro. Moreover, the use of biodegradable FDA-approved 
polymers as a core platform, offers the potential for the incorporation of other 
complementary active agents, and more seamless integration in pre-clinical and 
clinical studies. 
Lastly, while BAR-encapsulated and BAR-modified NPs demonstrate 
significant promise, their retention in the oral cavity is considered to be a challenge 
regardless of active agent and delivery vehicle. To address this challenge, our 
ongoing studies are focused on first developing NP formulations that can localize 
and retain BAR for longer durations in the oral cavity by using CafA-modified NPs 
to target Sg in oral niches.  
Certainly, the drug delivery system plays a vital role in controlling the 
therapeutic effect of the active agent through optimizing the rate of drug release. 
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Many dosage forms are designed to release the active agent immediately (rapid-
release) or provide delayed (prolonged) and extended-release products. 
Extended-release dosage forms can consist of sustained-release formulations that 
release agents over a specific time period, or controlled-release formulations that 
maintain the release of active agent at a constant rate for a specific duration194. 
In the long-term, we seek to formulate BAR-modified NPs or CafA-modified 
BAR-encapsulated NPs to more conveniently administer to the oral cavity in a 
mouthwash, oral varnish or gel formulation, with the goal of retaining BAR in oral 
niches for durations spanning 12-24 hr. In addition, our results utilizing BAR-
incorporated EFs to inhibit oral biofilm formation raise the possibility that this 
formulation can be developed in the form of strips or gum to release peptide over 
a time window of hours. We envision that formulating this extended-release 
platform may be applied once or twice daily to exert prophylactic effect in the oral 
cavity without the need to remove the fibers after application. 
Conclusion and Future Work 
Incorporation of BAR peptide in NPs provides gradual release of BAR 
peptide, while offering a platform to improve efficacy and potentially longevity in 
the oral cavity, compared to the transient activity of free BAR. In addition, BAR-
incorporated EFs may provide an alternative and specifically-targeted rapid-
release platform to inhibit and disrupt dual-species biofilms, that we envision may 
be applied once or twice daily to exert prophylactic effect in the oral cavity without 
the need to remove the fibers after application. BAR-modified NPs offered a 
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platform that provided higher localized concentration of BAR in the oral cavity via 
multivalent interactions. 
In future studies, we intend to examine different temporal administration 
regimens to optimize prevention and treatment approaches with these platforms. 
In addition, we plan to extend our studies to assess the kinetics of BAR-delivery 
vehicles in the oral cavity after gingival application. 
In the longer term, we seek to formulate these NPs into a mouthwash or gel 
for more convenient application to the oral cavity. In addition, we envision BAR-
EFs may be administered as dental strips or in gel form to degrade and avoid 
surgical removal after application. While existing products designed for localized 
periodontal prevention and treatment contain antibiotics, analgesic, or anesthetic 
cargos, we envision that this technology may offer a new way to deliver 
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